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Delivery has been the major obstacle for nucleic acid therapeutics, including the RNA 
interference (RNAi) approach.  Mixson’s lab has been focused on the development of 
a non-viral peptide-based delivery system, HK (histidine-lysine) polymers, which 
have shown promise as carriers of plasmids and small interference RNA (siRNA) in 
several cell lines and in tumor-bearing models.  In a previous study, a four-branched 
peptide, denoted H3K(+H)4b, with the predominant repeating -HHHK- sequence in 
the branch, has been shown to be the most effective and least toxic carrier in vitro and 
in vivo.   
Building on these results, I utilized different approaches including several structure 
and stability molecular characterization methods to study polyplex and to develop 
more effective carriers for improved therapy with siRNAs targeting malignancies. To 
  
understand the role of histidine in the stability of the H3K(+H)4b/siRNA polyplex,  
the physicochemical properties were investigated.  With the use of isothermal titration 
calorimetry and heteronuclear single quantum coherence NMR, histidines were 
shown to form hydrogen bonds with siRNA, which enhanced the stability and 
biological activity of the polyplexes.  In addition, to enhance resistance to nucleases 
and to target the tumors selectively, H3K(+H)4b was chemically modified with 
different patterns of polyethylene glycol (PEG) and cyclic RGD (Arg-Gly-Asp, 
cRGD) peptide conjugates.  The luciferase marker gene expressed stably by tumor 
xenografts in mouse models was targeted in order to evaluate the efficacy of HK 
carriers of siRNA that differed in location and number of cRGD-PEG attachments.  
The most effective carrier was (RGD-PEG)4H3K(+H) (RP-HK), which has a cRGD-
PEG on each of its four terminal branches.  Consistent with its prolonged stability, as 
observed by pharmacokinetic studies, the RP-HK polyplex down-regulated luciferase 
activity in tumor xenografts by nearly 70% compared with the untreated group.   
Subsequently, the RP-HK polyplex was used to target the Raf-1 oncogene, an 
important mediator of tumor cell growth and angiogenesis.  As in the luciferase 
studies, the polyplex reduced Raf-1 mRNA by more than 75%, and more importantly, 
the treatment inhibited the tumor growth by 60% in a mouse model.  We anticipate 
that further design and engineering of HK carriers will improve the predictability and 
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Although siRNA has emerged as an alternative therapeutic for cancer, a significant 
obstacle has been the lack of an efficient and low-toxic carrier for systemic delivery.  
To deliver siRNA, Mixson’s lab has focused on the development of biodegradable 
polymers, including linear and branched histidine-lysine (HK) peptides.  These 
peptides synthesized by solid phase methods, have the advantage that their sequences 
are well-defined and manipulatable for functional and biophysical studies.  To 
improve efficacy and establish an evidence-based approach for carrier development, 
it is essential to characterize the biophysical properties of peptides differing in 
sequence and/or number of branches.  In addition to passive tumor targeting, carriers 
have evolved to “functionalized” vehicles with greater stability and specificity toward 
their targets.  
 
The formation of small and compact nanoparticles is critical for siRNA-mediated 
gene silencing in vitro and in vivo.  Previously, Mixson’s lab has reported that 
variations in the amino acid sequence and buffering milieu affect the interaction 
between the HK peptide and siRNA to form polyplexes (Leng and Mixson 2005; 
Leng, Scaria et al. 2005; Leng, Scaria et al. 2006).  The biophysical properties, such 




another and more importantly with in vivo inhibition efficiency to define general 
characteristics of an effective and/or ineffective carrier. 
 
Although HK peptides are capable of packaging negatively charged siRNA, poor 
pharmacokinetic properties of polyplexes have always been obstacles.  A common 
strategy to protect the siRNA sterically from degradation is the conjugation of 
polyethylene glycol (PEG) to the polyplex.  PEG enhances the stability by adding a 
brush-like layer, coating the outside of the polyplex (Caliceti and Veronese 2003).  
Moreover, PEG also increases the hydrophilicity of the polyplex by creating a 
hydration film which significantly decreases their clearance by the reticuloendothelial 
system.  In addition, a ligand is often conjugated with the carrier to increase the 
specificity toward the cell of interest and to reduce the off-targeting effects.  Because 
αvβ3 and αvβ5 integrins are expressed by MDA-MB-435 cells and their angiogenic 
vessels, their cognate ligand cyclic RGD (cRGD) peptide may enhance receptor-
mediated internalization of the polyplex (Arap, Pasqualini et al. 1998). 
 
This study characterized critical physicochemical features of HK peptides that 
enhance endocytosis of the polyplex.  Furthermore, by adding cRGD-PEG conjugates 







1.2 RNA Interference and siRNA 
 
Eukaryotic cells have evolved sophisticated pathways to control gene expression, 
including RNA interference (RNAi). RNAi is a biological mechanism in which the 
translation of mRNA is interrupted by specific regulatory RNA.  In general, this 
mechanism is initiated by Dicer-induced cleavage of double stranded premature micro 
RNA (pre miRNA) into micro RNA (miRNA) or small interfering RNA (siRNA).  In the 
cytoplasm (Fig. 1.1), loading of the catalytic protein RNA-induced silencing complex 
(RISC) with miRNA or siRNA unwinds the duplex and the antisense strand can then 
target a specific mRNA, leading to degradation.  RNAi, which has been utilized to 
down-regulate aberrant disease-causing genes and to study genes important for signal 
transduction pathways, has emerged as a promising research and therapeutic strategy 
(Fire, Xu et al. 1998).   
 
RNAi has been used as a therapeutic by two approaches: chemically synthesized siRNA 
or vector-based short hairpin RNA (shRNA).  Whereas siRNA is usually delivered by 
non-viral methods, shRNA expression plasmids can be delivered by both viral and non-
viral approaches.  Compared to siRNA, vectors expressing shRNA have to overcome 
additional barriers such as import of plasmids into the nucleus and multiple enzymatic 
processing before the incorporation of shRNA by RISC.  Moreover, overexpression of 
shRNA may saturate endogenous miRNA machinery, leading to toxicity (Grimm, Streetz 





Fig. 1.1. Mechanism of siRNA-mediated mRNA degradation (Leng, Woodle et al. 
2009) 
 
Despite significant advances and investment devoted to cancer research, many cancers 
have a high mortality rate and many molecular aspects of the disease are still poorly 
understood.  Recent advances in the Human Genome Project have provided 
comprehensive insight into genetic diseases and the function of specific genes.  The 
molecular origins and intracellular signal transduction pathways of cancers can be 
characterized by examination of tumor specimens from the individual patient, giving rise 
to the advent of personalized medicine.  With features of safe and specific gene 
regulation, RNAi-based medicine can potentially target any oncogene, enabling its 





1.2.1 Small interfering RNA (siRNA) 
siRNAs are double stranded RNA duplexes that usually range in size between 19 and 
29 base pairs (bp).  After the active siRNA of 19-23 bp is incorporated into RNA-
induced silencing complex (RISC), an endonuclease of RISC, Argonaute 2, together 
with the antisense strand of the RNA recognizes and cleaves the target mRNA in a 
catalytic manner (Grimm, Streetz et al. 2006; Snove and Rossi 2006).    
 
siRNAs larger than 23 bp must be enzymatically processed by the endonuclease Dicer 
to a size of 23 bp or less prior to their incorporation into the RISC complex.  One of 
the more troublesome aspects initially with introduction of RNAi into mammalian 
cells was non-specific silencing through cytokine induction by duplexes of 30 bp or 
larger; this obstacle was overcome to a large extent with the discovery that smaller 
RNAi duplexes between 19 and 30 bp caused specific silencing without marked 
cytokine induction.  Nevertheless, the smaller siRNAs can still induce cytokines 
depending on the sequence of the siRNA and its carrier.  For example, cationic 
liposomes in combination with siRNA are particularly potent carriers of siRNA.  
Induction of cytokines as a result of these siRNA polyplexes is usually dependent on 







1.3 Systemic Delivery of siRNA 
 
Despite the promise of siRNA as a therapeutic agent, there are three significant 
problems that need to be solved before siRNA can be used systemically to treat 
malignant diseases effectively: 1) prevent or retard degradation of siRNA by 
nucleases in the bloodstream; 2) specific delivery to the diseased target to prevent 
side effects in non-targeted tissues; and 3) transport of highly negatively charged 
siRNA across cellular membranes into the cytosol of the target tissue.  To overcome 
these obstacles, it is essential to stabilize siRNA and facilitate its localization and 
cellular uptake into the malignant tissue.   Two major strategies (chemical 
modification and physical delivery) for “naked” siRNA delivery will be introduced in 
the following paragraphs. 
 
1.3.1 Chemical modification of siRNA 
Naked siRNA is vulnerable in exposure to nuclease while being administered 
systemically.  To improve the pharmacokinetic (PK) properties and minimize the 
possibility of an immunostimulatory response due to siRNA (Behlke 2008), a variety 
of chemical modifications have been made on the 2’-OH group of the ribose.  The 
most common modifications, including 2’-O-methyl, 2’-fluoro, and 2’-hydrogen (Fig. 
1.2), have been studied to compare the gene silencing activity, serum stability, and 
immunostimulatory effect versus unmodified siRNA (Chiu and Rana 2003).  The 2’-




siRNA without interference with silencing activity (Morrissey, Lockridge et al. 2005; 
Robbins, Judge et al. 2008; Chou, Leng et al. 2011). In addition, 2’-O-methyl-
modified siRNA also significantly reduced cytokine induction by antagonizing 
TLR7/8 receptors (Morrissey, Blanchard et al. 2005; Morrissey, Lockridge et al. 
2005; Robbins, Judge et al. 2007; Robbins, Judge et al. 2008).  Other modifications 
such as locked nucleic acids (LNAs) (Elmen, Thonberg et al. 2005) and 
phosphorothioate linkages (Fig. 1.2) at the 3’ end have also resulted in resistance to 
exonucleases or caused off-target effects (Jackson, Burchard et al. 2006). Even 
though chemical modifications have been applied to move siRNA therapeutics toward 
the clinic, most current approaches cannot be universally applied to any gene of 
interest.  Furthermore, bulkier modifications on the sugar moiety may be correlated 
with decreased siRNA activity. 
  




1.3.2 Physical delivery 
The physical methods for siRNA delivery are relatively convenient and may avoid 
nonspecific immune stimulation.  In general, this strategy induces pores in cell 
membranes for influx of naked siRNA or complexes intracellularly.  Electroporation 
has been a useful tool for DNA or siRNA transfection in vitro.  For in vivo use, 
electroporation is limited for local delivery to tissues such as brain (Jackson, 
Burchard et al. 2006) or retina (Matsuda and Cepko 2004).  By rapidly injecting a 
large volume of physiological fluid containing naked nucleic acids, the hydrodynamic 
delivery approach increases vascular pressure to cells in highly vascularized organs, 
such as lungs, liver, or kidneys.  There have been multiple successful and safe 
applications for hydrodynamic gene delivery to rodents (Liu, Song et al. 1999; Zhang, 
Budker et al. 1999) or animals as large as pigs (Yoshino, Hashizume et al. 2006; 
Kamimura, Zhang et al. 2010) and non-human primates (Zhang, Budker et al. 2001).  
Nonetheless, it is unlikely that this method can be well-tolerated by humans except 
for localized delivery.   
 
1.4 Non-viral Carriers 
In addition to chemical modification and physical delivery of siRNA, non-viral 
cationic carriers that form self-assembled nanoplexes with negatively charged siRNA 






Cationic liposomes are one of the earliest carriers used for gene delivery and have 
been commercialized as efficient in vitro cell transfection agents such as 
Lipofectamine 2000, DMRIE-C, Oligofectamine (Invitrogen), DOTAP (Roche 
Applied Science), X-tremeGene (Roche), siRPORT NeoFx (Ambion), RNAifect 
(Qiagen), and GeneSilencer (Genlantis).  Moreover, they have been used successfully 
to deliver siRNA in animal models (Chien, Wang et al. 2005; Morrissey, Lockridge et 
al. 2005; Geisbert, Hensley et al. 2006; Zimmermann, Lee et al. 2006; Aigner 2008; 
Peer, Park et al. 2008).  Although cationic lipids are relatively affordable and quickly 
formulated, immunogenicity and lack of biocompatibility have become the most 
significant hurdles for the application of cationic lipoplexes in vivo.   
 
To reduce cytokine induction by systemically administered lipoplex, Huang’s group 
has incorporated highly basic protamine to minimize direct ionic interaction between 
siRNA and 1,2-dioleoyl-3-trimethylammonium propane (DOTAP, Fig. 1.3) (Li, 
Chono et al. 2008).  By further modifying the liposome-protamine-DNA (LPD) with 
PEG and anisamide ligand, luciferase expression in a lung cancer metastasis model 
was inhibited by 80% by treatment with LPD and luciferase siRNA complex.  
Interestingly, while protamine or DOTAP in complex with siRNA individual each 
induces significant cytokine response, LPD/siRNA shows reduced immunogenicity.  
Another PEGylated cationic liposome preparation, stable nucleic acid lipid particle 
(SNALP), has been used to reduce viral infections (HBV siRNA) (Morrissey, 




al. 2006) in mice or in non-human primates significantly.  Several phase I clinical 
trials have been initiated with the use of SNALP-based products (Alsina, Tabernero et 
al. 2012; Strumberg, Schultheis et al. 2012).  
 
Since toxicity of cationic liposomes has been correlated to their charge density, 
several groups have developed neutral liposomes with 1,2-dioleoyl-sn-glycero-3-
phosphatidylcholine (DOPC, Fig. 1.3).  Neutral liposomes are prepared by mixing 
DOPC with siRNA in organic solvent, and the mixture is frozen, lyophilized, and re-
hydrated for injection.  DOPC-siRNA lipoplexes have been used to reduce the tumor 
growth effectively by targeting EPHA2 (ovarian), thrombin receptor (melanoma), 
interleukin-8 (ovarian), and focal adhesion kinase (ovarian) oncogenes (Landen, 
Chavez-Reyes et al. 2005; Halder, Kamat et al. 2006; Landen, Merritt et al. 2006; 
Merritt, Lin et al. 2008; Villares, Zigler et al. 2008).  The second generation of neutral 
liposomes is coated with hyaluronic acid to prolong the half-life of lipoplexes in the 
circulation.  Moreover, Peer and colleague also conjugated hyaluronic acid-stabilized 
DOPC with β7 antibody to target activated leukocytes and suppress inflammation 
specifically (Peer, Park et al. 2008).   
 
1.4.2 Cationic polymers 
Synthetic cationic polymers (Fig. 1.3), such as polyethyleneimine (PEI) or 
polyamidoamine (PAMAM) that has branched structure and amine groups with 
efficient binding to siRNA, have been extensively investigated for in vitro cell 




cytotoxicity have been the major obstacles limiting the application of these branched 
polymers.  The strategies to reduce toxicity and non-specific cell internalization of 
PEI polyplexes is similar to those for cationic liposomes.  Modification with 
polyethylene glycol (PEG) or hyaluronic acid (Jiang, Park et al. 2008; Li, Chen et al. 
2008) likely shields the polyplexes to circumvent their interaction with the 
reticuloendothelial system and blood components.  Even though a study showed no 
extended half-life with PEGylated PEI (Merkel, Librizzi et al. 2009), Kataoka’s group 
has utilized spinning disk confocal microscopy to demonstrate that PEGylation of PEI 
prevents aggregation of polyplexes in the circulation (Nomoto, Matsumoto et al. 
2011).  Moreover, to increase the tumor specificity, investigators have conjugated 
various ligands, including cRGD peptide (αvβ3) (Schiffelers, Ansari et al. 2004; Waite 
and Roth 2009), folate (folate receptor) (Kim, Mok et al. 2006), or Luteinizing 
Hormone-Releasing Hormone (LHRH receptor) (Minko, Patil et al. 2010).  Modified 
polyplexes are frequently preferred because of their greater specificity and efficacy of 
tumor inhibition. 
 
1.4.3 Other synthetic carriers 
Micelles formed by block copolymers such as poly(ethylene oxide)-block-poly(ε-
carpolactone) (PEO-PCL) or poly[2-(dimethylamino)ethyl methacrylate]-block-
poly(ε-caprolactone)-block-poly[2-(dimethylamino)ethyl methacrylate] 
(PDMAEMA–PCL–PDMAEMA) have been explored to deliver siRNA, as well as 
siRNA-Paclitaxel co-delivery to tumor xenografts (Zhu, Jung et al. 2010; Sun, Du et 




with siRNA through disulfide bonds (Rosi, Giljohann et al. 2006; Giljohann, Seferos 
et al. 2009; Lee, Green et al. 2009).  Although these materials have not been applied 
for systemic delivery of siRNA, topically-administered gold-siRNA conjugates have 
been shown to be effective for knockdown of EGFR in epidermal cells in vivo 
(Zheng, Giljohann et al. 2012).  Single walled carbon nanotube (SWNT) has shown 
the ability to penetrate mammalian cells without significant cytotoxicity (Pantarotto, 
Briand et al. 2004).  Phospholipids and PEG functionalized SWNT/siRNA polyplex 
has been intratumorally injected in a mouse model, resulting in tumor inhibition of 
70% (Zhang, Yang et al. 2006).  Although carbon nanotubes are highly organized and 
chemically and mechanically stable, their biodegradability remains a challenge.   
 
1.4.4 Natural cationic polymers  
There are several vehicles derived from natural products for siRNA delivery currently 
being studied in preclinical and clinical trials, including cyclodextrin (Fig. 1.3) 
(Heidel, Yu et al. 2007), protamine (Song, Zhu et al. 2005), atelocollagen (Mu, 
Nagahara et al. 2009), and chitosans (Rudzinski and Aminabhavi 2010).  Although 
natural cationic polymers are generally biodegradable, these polymers also show 
relatively lower gene silencing activity compared with PEI.  As a result, approaches 
have been explored to increase siRNA delivery by enhancing the surface recognition 
of target cells by these polyplexes.  Various ligands and antibodies have become 
important components during development of these natural polymers for siRNA 




polymer-based carrier that has been approved for clinical trials (Davis, Zuckerman et 
al. 2010).   
 






Peptides composed of charged residues such as lysines, arginines, and histidines, have 
been extensively explored for gene delivery.  Linear poly-L-lysine (PLL, Fig. 1.3) 
was one of the earliest polypeptides used for transfection of plasmid, showing 
effective gene transfer in the liver (Perales, Ferkol et al. 1994).  In many cases, 
however, linear PLL is not an effective carrier for siRNA or DNA due to the 
instability of the polyplex and its limited ability to escape the endosome.  Dendritic 
PLL was then developed for effective siRNA delivery (Watanabe, Harada-Shiba et al. 
2009). The unmodified PLL-based carriers are attractive, although there has been no 
successful case in vivo other than the transfection of hepatocytes. 
 
Kataoka’s group has modified the PLL with cRGD-PEG at the N-terminus and with 
2-iminothiolane on the amines of side chains of lysines (Christie, Matsumoto et al. 
2012).  After this thiol-containing polymer forms polyplexes with siRNA, the 
stability and structure of micelles can be enhanced through disulfide cross-linking.  
These stabilized micelles incorporating VEGF siRNA showed 50% reduction in 
VEGF mRNA expression and 80% inhibition of tumor growth.  There was no 
significant difference in body weight when siRNA-treated mice were compared to 
untreated. 
 
Cell penetrating peptide (CPP), containing arginines, was derived from a transcription 
factor of HIV, the transactivator of transcription (TAT) protein (Frankel and Pabo 




induce macropinocytosis (Lundberg, Wikstrom et al. 2003; Nakase, Niwa et al. 
2004).  Another possible mechanism of internalization not unique to polyarginine 
polyplexes is the interaction between positively charged peptide and anionic 
phospholipid of the cell surface to cross the cell membrane (Esbjorner, Lincoln et al. 
2007; El-Sayed, Khalil et al. 2008; Ziegler and Seelig 2008).  A number of CPP-
siRNA conjugates have demonstrated antitumor efficacy by inhibiting oncogenes in 
animal models (Chiu, Ali et al. 2004; Davidson, Harel et al. 2004; Jiang, Olson et al. 
2004).  To downregulate target genes effectively in vivo, polyarginine can form stable 
complexes with siRNA using the peptide alone (R15, a 15-mer polyarginine) (Kim, 
Kim et al. 2010), by conjugating the peptide (R9, a 9-mer polyarginine) to cholesterol 
(Kim, Christensen et al. 2006) or rabies virus glycoprotein (RVG) (Kumar, Wu et al. 
2007). 
 
1.4.6 siRNA conjugates 
In contrast to the cationic polymers or liposomes that form complexes by condensing 
negatively charged nucleic acids, another approach to delivery of siRNA is to 
conjugate stabilizing and/or tissue-targeting materials, such as cholesterol, PEG, or 
aptamers to siRNA.  Conjugation of cholesterol (Wolfrum, Shi et al. 2007) or α-
tocopherol (Nishina, Unno et al. 2008) to siRNA significantly extends serum half-life 
from 6 to 45 min, compared with unconjugated siRNA.  These lipophile-conjugated 
siRNA are particularly effective for uptake into hepatocytes.  Kim and colleagues 
have developed an LHRH-PEG-siRNA conjugate that self-assembles into micelles 




not been tested in animal models, it shows marked VEGF silencing at least in A2780 
cells. 
 
Aptamers are structured DNA or RNA molecules that can be engineered through 
SELEX (systematic evolution of ligands by exponential enrichment) to target various 
receptors, such as prostate-specific membrane antigen (PSMA) (Dassie, Liu et al. 
2009) and human epidermal growth factor receptor 2 (Her2) (Thiel, Hernandez et al. 
2012).  Furthermore, aptamers have been conjugated to PEG-PEI to co-deliver 
doxorubicin and Bcl-xl siRNA (Kim, Jung et al. 2010).  Aptamer siRNA conjugates 
have emerged as a promising delivery vehicle for siRNA with increased stability 
against nucleases, specific binding, and low immunogenicity. The library of aptamers 
remains expandable to target other receptors highly expressed by cancer cells 
 
1.5 Histidine-lysine Rich (HK) Peptides 
 
Mixson’s lab has focused on developing an effective in vitro and in vivo vehicle for 
small interfering RNA (siRNA).  To accomplish this, we have synthesized and 
screened a number of histidine-lysine rich (HK) peptides to test their ability to carry 
siRNA.  In this context, the lysines are essential for binding siRNA, and the histidines 
are important for buffering and may aid in the release of siRNA and disruption of 
endosomes (Chen, Zhang et al. 2001).  In contrast to PEI, in which the ethyleneimine 




originally designed to have its buffering and nucleic acid binding properties on 
different groups (histidine and lysine).  This enables the ratio of the histidines to 
lysines to be varied to tailor this carrier for different forms of nucleic acids (siRNA 
vs. plasmids) and for different cells. 
 
In a previous study, several HK polymers were synthesized and examined to compare 
their ability to deliver siRNA targeting β-galactosidase (β-gal) expressed in SVR-
bag4 cells (Chen, Zhang et al. 2001; Leng and Mixson 2005).  An eight-branched 
polymer H3K8b with predominant repeating group -HHHK- was a more effective 
carrier than H3K(+H)4b and H2K4b.  In a subsequent study, we examined various 
HK polymers as carriers of a Raf-1 siRNA.  Raf-1 is an important signal transduction 
molecule that has an significant role in the growth of many different malignant cells 
(including MDA-MB-435 cells) and on promotion of tumor angiogenesis.  One 4-
branched polymer, H3K(+H)4b, whose predominant repeating pattern is -HHHK-, 
was determined to be an effective carrier of siRNA: the H3K(+H)4b/siRNA 
polyplexes targeting the Raf-1 oncogene inhibited tumor cell growth both in vitro and 
in vivo.  Interestingly, H2K4b, which has a higher percentage of lysine, was the most 
effective carrier to deliver plasmids, but it was not an effective carrier of siRNA.  The 
results show that the efficacy of different HK polymers as carriers of plasmids or 
siRNA varies and is dependent on the sequence pattern and branching of the 





Although the eight-branched HK polymer with siRNA was slightly more effective 
than the four-branched HK carrier in silencing its target, we selected the H3K(+H)4b 
for further siRNA studies in vivo based partly on its relative ease of synthesis.  In 
order to prevent aggregation and to target the tumor with the polyplex selectively, we 
proposed to modify the HK polymers with polyethylene glycol (PEG) and a cyclic 
RGD (Arg-Gly-Asp) peptide.  While PEG increases the hydrophilicity of molecule, 
cyclic RGD peptide is expected to target the integrin, αvβ3 (Wong, Mueller et al. 
1998).  
  
As described in this dissertation, H3K(+H)4b as a carrier of siRNA has several 
advantages over other HK carriers.  Although the eight-branched H3K8b was found 
to be an equally effective carrier of siRNA (as H3K(+H)4b), the eight-branched 
carrier was difficult to PEGylate at specific locations, perhaps due to steric hindrance.  
The eight-branched H3K8b polymer has proved relatively resistant to addition of 
cysteines to its terminal branches, which is a necessary step before the addition of 
cRGD-PEG.  In contrast, the four-branched HK polymer, H3K(+H)4b, can easily be 
modified with cRGD-PEG at specific locations by adding N-terminal cysteines to 
each of the branches or by adding a C-terminal cysteine to its core.   When cysteines 
are added to each of the four branches of H3K(+H)4b, there are 4 cRGD-PEG per 
polymer, but when a cysteine is added off the 3-lysine core, there is only one cRGD-
PEG per molecule.   The ability to add cysteines at specific locations enables careful 
control as to where the cRGD-PEG molecules will be inserted within the H3K(+H)4b 




1.6 siRNA-mediated cancer therapeutics in clinical trials 
Although several previously mentioned siRNA lipoplexes or polyplexes have shown 
translatable preclinical activity against cancers, there have been only five cancer 
clinical trials using nanoparticle-formulated siRNA therapy.  These include 
transferrin-modified cyclodextrin (CALAA-01), stable nucleic acid lipid particle 
(SNALP; ALN-VSP02 and TKM080301), multi-lipid liposomes (Atu027), and 
neutral liposome (siRNA-EphA2-DOPC) (http://www.clinicaltrials.gov).   
 
The transferrin-modified cyclodextrin is the only polymer-based siRNA drug 
approved for clinical trials.  While targeting the luciferase expression of tumor 
xenografts, it reduces 80% of luciferase activity with single dose of the polyplex 
(Bartlett and Davis 2006; Bartlett, Su et al. 2007).  In phase I clinical trials, the 
melanoma patients received CALAA-01 have shown reduced expression in mRNA of 
M2 subunit of ribonucleotide reductase (RRM2) compared with pre-treated tumor 
tissues.  Relatively poor pharmacokinetic properties has been a potential factor 
limiting the therapeutic activity of CALAA-01.  Although HK/siRNA and 
cyclodextrin/siRNA polyplexes have a similar serum half-life, the HK polyplex is 
cleared by the kidneys significantly later than the cyclodextrin polyplex (2 h vs. 20 
min) suggesting a different mechanism of metabolism (Zuckerman, Choi et al. 2012; 
Chou, Leng et al. 2013). 
 
As described previously, SNALP formulated siRNA nanoparticles have effectively 




used to target kinesin spindle protein (KSP), polo-like kinase 1 (PLK1), and VEGF in 
malignant hepatoma (Judge, Robbins et al. 2009).  While SNALP has a circulation 
half-life greater than 18 h (Morrissey, Lockridge et al. 2005), the majority of the 
lipoplexes is internalized by the liver and spleen.  It is suspected that these lipoplexes 
may not be degraded but accumulate in tissues, leading to liver and spleen toxicity, 
especially with prolonged dosing.  In addition, the application for treatment of solid 
tumors may be limited if SNALP has the preference for liver or spleen uptake.  
Sood’s group at MD Anderson Cancer Center has shown that siRNA-EphA2-DOPC 
in combination with paclitaxel results in synergistic anti-tumor efficacy (Landen, 
Chavez-Reyes et al. 2005).  Importantly, the dosage of these cationic liposomes used 
in the preclinical study is 150 µg/kg which is ten times lower than SNALP or other 
cationic liposomes.  A low-dose treatment that maintains activity is likely to enhance 
the translatability of DOPC in clinical trials.  Moreover, the production of 
DOPC/siRNA lipoplexes involves lyophilization, which is easier to transport, store, 
and maintain stability of the lipoplexes.  In general, the cost of synthesis of liposomes 
is 5 to 10 times cheaper than synthetic polymers or peptides in the laboratory scale 
which is an advantage of liposomal platforms. 
 
Currently, none of these five siRNA therapeutics targeting cancers has advanced to 
phase II clinical trials.  It is too early to determine which of these delivery systems 
will be effective and receive FDA approval.  In addition to the antitumor efficacy 
(e.g. tumor volume changes, density/opacity changes, and differential distribution 




siRNA therapeutics have to improve their bioavailability, specificity, and 
affordability to tackle formidable challenges presented by the complexity of cancers. 
 
1.7 Biophysical Characterization of Carrier/siRNA Complexes 
 
As many carriers have been explored for their ability to deliver siRNA, correlations 
among the physicochemical properties and the efficacy of siRNA complexes have 
emerged. These correlations will become indispensable for future improvements in 
carriers as the field transition from trial and error to principle-based development.  
For example, multiple studies have shown that passive accumulation in the tumor 
through the enhanced permeability and retention (EPR) effect is maximal with a 
nanoparticle size less than 150 nm (Noguchi, Wu et al. 1998; Ishimoto, Takei et al. 
2008; Melnikova, Villares et al. 2008; Villares, Zigler et al. 2008).  Moreover, the 
endocytosis pathway also depends on particle size (Medina-Kauwe, Xie et al. 2005).  
Critical features determined by structure, inter/intra-molecular forces, and complex 
self-assembly mechanism will likely aid the development of more effective carriers.  
In addition, the characteristics of suspension media, including temperature, pH, ionic 
strength, and adulterates such as endotoxins also play a role in the translation of 
siRNA therapy toward the clinic.  In the following paragraphs three techniques, zeta 
potential, isothermal titration calorimetry (ITC) and nuclear magnetic resonance 






1.7.1 Zeta potential 
The zeta potential is related to the surface charge on the nanoparticle and is greatly 
influenced by the ionic strength of the solution.  More specifically, charged particles 
attract counterions as well as ions that form an electrical double layer near the surface 
of particles (Fig. 1.4).  The inner plane of the double layer (stern layer) consists 
tightly bound couterions whereas the ions and counterions diffuse freely between the 
outer layer (slipping plane) and the bulk fluid as a balance of electrostatic force and 
thermal motion.  The zeta potential of a nanoparticle is the electrical charge 
difference between the slipping plane and the solution. 
 
Zeta potential is measured by the electrophoretic mobility of the nanoparticle 
determined with light scattering.  The electrostatic repulsion or attraction between the 
particles depends on the magnitude of zeta potential.  For electrostatically stabilized 
dispersions, the value of the zeta potential is generally greater than 20 mV.  
Therefore, it is an appropriate index for stability, and it can be used to optimize the 





Fig. 1.4. Zeta potential and electric double layer 
 
Because cell membranes consist of negatively charged molecules such as 
glycoaminoglycans, cationic polyplexes or lipoplexes are likely to be internalized in 
the cell through electrostatic interactions (Mislick and Baldeschwieler 1996).  
However, there are several studies showing effective transfection efficacy in vitro and 
in vivo with negatively charged complexes, including siRNA coated gold 
nanoparticles and anionic liposomes (Rosi, Giljohann et al. 2006; Mozafari, Reed et 
al. 2007; Seferos, Prigodich et al. 2009).  Moreover, Whitehead and colleagues have 




potential and in vivo gene silencing (Whitehead, Matthews et al. 2012) based on a 
study collected more than 300 data points.  While there is a clear correlation between 
zeta potential and transfection in vitro, this correlation is less clear in vivo. Scavenger 
receptors are known to play an important role in the uptake of anionic particles in 
livers (Furumoto, Nagayama et al. 2004).  The cancer cells may also express similar 
receptors that interact with negatively charged particles.  In addition, the high 
concentration of serum in vivo likely masks the intrinsic zeta potential and influence 
transfection properties of the complex.  Therefore, zeta potential should be 
characterized for each type of carrier to correlate with other properties of polyplexes, 
such as binding and release profiles, to determine the optimal formulation. 
 
1.7.2 Isothermal titration calorimetry (ITC) 
The binding interaction between polycations and siRNA has been extensively studied 
by gel electrophoresis, fluorescent dye exclusion assay, and isothermal titration 
calorimetry (ITC).  Gel electrophoresis is the most common approach to determine 
the amount of siRNA neutralized or condensed by cations.  Although gel 
electrophoresis analysis is relatively quick and convenient, it is difficult to quantify 
binding affinity between carriers and nucleic acids.  Molineux et al. were the first 
group to monitor dynamic binding interaction based upon the change of fluorescence 
properties (Molineux, Pauli et al. 1975; Lohman and Overman 1985).  By plotting the 
fluorescence intensity versus concentration of DNA, the binding free energy and the 
stoichiometry of binding can be quantified.  The binding affinity determined by 




change of DNA or non-specific binding between carriers and fluorochromes.  In 
contrast, ITC directly measures the heat exchange, the enthalpy, accompanying any 
chemical reaction and physical change, allowing the determination of Gibbs free 
energy, entropy, and stoichiometry.  Therefore, ITC has emerged as an appropriate 
method to analyze interactions between biomolecules.    
 
Binding interaction is the building block of self-assembled polyplexes.  ITC can be 
used to dictate critical features correlated with cell internalization, endosomal escape, 
and gene silencing efficacy.  Lohman’s group has studied binding between numerous 
peptides and nucleic acids by utilizing ITC at a range of salt concentrations.  They 
have shown that, for linear peptides of similar length, binding affinity is totally 
dependent on charge density (Mascotti and Lohman 1992).  In contrast, exothermicity 
is independent of charge density but dependent on sequence when comparing the 
nucleic acid binding of oligolysines to oligoarginines (Mascotti and Lohman 1997).  
The data suggest that arginines form hydrogen bonds with siRNA to enhance the 
stability. Interestingly, the transfection ability of cell-penetrating peptides, which 
contain arginine residues, may correlate at least in part with hydrogen bond 
formation.  Prevette and colleagues further analyzed the thermodynamics of 
carbohydrates and DNA binding to derive the contribution of ionic and non-ionic 
interaction to the binding free energy (Prevette, Kodger et al. 2007).  Although direct 
evidence is lacking, non-ionic interaction stabilizing the polyplex has been suggested 





In addition to intermolecular forces, the complexation of carriers and DNA or siRNA, 
which occurs after the initial binding, has also been monitored by ITC.  Bloomfield et 
al. have observed a multi-stage binding (double endothermic peaks) in the study of 
cobalt hexamine and plasmids (Matulis, Rouzina et al. 2000).  The first stage is a 
result of ligand-DNA monomer binding and the second transition is attributed to 
charge neutralization-induced reorganization and condensation.  Although a more 
reliable model of complex self-assembly depends on complementary computational 
simulations and other biophysical characterization, several groups investigating 
polycation/nucleic acid binding have observed similar energetic transitions (Jensen, 
Mortensen et al. 2010; Utsuno and Uludag 2010; Zheng, Pavan et al. 2012).  This 
mechanism of nucleic acid packaging can be correlated to the stability of complexes 
in vitro and in vivo.  Notably, although the mechanism of complexation is an 
important factor for cell internalization and endosomal escape, considerably more 
information on carriers will be required to utilize thermodynamic profiles for 
development.   
 
1.7.3 Nuclear magnetic resonance (NMR) 
While binding interaction can be investigated by ITC macroscopically, binding 
epitopes on biomolecules and the structural rearrangement induced by binding are 
often characterized by nuclear magnetic resonance (NMR).  The changes in NMR 
parameters, including chemical shift, coupling constant, and relaxation, provide the 
basis for analyzing binding events.  For example, the 1H nuclei of bound 




tumbling.  Therefore, peak-broadening is indicative of complex formation and can be 
analyzed to quantify binding affinity. 
 
Although the acquisition of the 1D 1H-NMR spectra of biomolecules with or without 
binding partners has been used to characterize binding, the proton signals alone 
typically cannot afford high-resolution structural and dynamic properties.  Isotope-
labeling (15N and/or 13C) of biomolecules is needed to study heteronuclear couplings 
(1H-15N or 1H-13C).  15N labeling is extensively applied in proteins since 
heteronuclear 1H-15N correlations can be observed from the backbone amide of each 
amino acid, except proline.  In particular cases such as with histidine, 1H-15N signals 
in the side-chain can also be detected.   
 
1.7.4 Heteronuclear single quantum coherence (HSQC)  
Although the histidines in HK peptides have been hypothesized to mediate non-ionic 
bonds with nucleic acids to enhance the stability of polyplex, direct evidence has been 
lacking.  Because histidine is so important in physiologically relevant events such as 
enzymatic reactions or ion channel transport, 15N NMR spectroscopy methods have 
been designed specifically to study hydrogen bonding by the imidazole side chain.  
The sensitivity of the 1H-15N cross-peaks of the histidine side chain to hydrogen 
bonding has been used to study hydrogen bonding in serine protease (Bachovchin 
1986; Farr-Jones, Wong et al. 1993), triosephosphate isomerase (Lodi and Knowles 
1991), and a membrane component of the phosphotransferase system (Van Dijk, 





The two nitrogens (Nδ1 and Nε2) and two carbon-attached hydrogens (Hε1 and Hδ2) 
result in four correlated 1H-15N cross-peaks in the heteronuclear spectrum.  To 
analyze and interpret the 1H-15N couplings, it is essential to know the 15N chemical 
shifts of various ionic forms of the imidazole ring (Fig. 1.5): deprotonated (type β) 
nitrogen at 249.5 ppm; protonated (type-α) nitrogen at 167.5 ppm; and charged and 
protonated (type α+) nitrogen at 176.5 ppm (Bachovchin 1986; Van Dijk, Scheek et 
al. 1992; Pelton, Torchia et al. 1993).  The three-bond 3JNδ1Hδ2 coupling usually gives 
rise to relatively weaker intensity (Fig. 1.5), thus, allowing the assignment of each 
cross-peak.   
 
Type-α and type-β nitrogen chemical shifts are observed when there is no equilibrium 
between the two tautomers (Fig. 1.5 A and B), usually seen in folded proteins that 
have histidine buried in a hydrophobic pocket.  If the histidine residue is accessible to 
solvent, both tautomers will be present and the favorable tautomeric form is pH-
dependent.  Studies have shown that the tautomeric equilibrium of histidines can be 
quantified based on the difference between the Nδ1 and Nε2 chemical shifts 
(Bachovchin 1986; Van Dijk, Scheek et al. 1992).  For example, if the Nδ1 and Nε2 
chemical shifts are found at 222 and 174 ppm, respectively, then 80% of this histidine 
exists in the Nε2-H tautomeric form. The pKa of a histidine can be determined by 
curve-fitting of 1H and 15N chemical shifts over a range of pH with non-linear least 




For titratable histidines, a model has established that hydrogen bonding will produce 
perturbation of 15N chemical shifts in the direction similar to 
protonation/deprotonation (Schuster and Roberts 1979).  Up to 10 ppm downfield or 
upfield changes of chemical shift can be observed for a hydrogen bond donor or 
acceptor, respectively. 
 
Fig. 1.5. Schematic diagram of tautomeric and protonated forms of histidine, their 











Chapter 2: Mediation of Silencing Activity and Stability of the 
HK/siRNA Polyplex by Hydrogen Bonds between Histidine 




Branched peptides containing histidines and lysines (HK) have been shown to be 
effective carriers for DNA and siRNA.  We anticipate that elucidation of the binding 
mechanism of HK with siRNA will provide greater insight into the self-assembly and 
delivery of the HK/siRNA polyplex.  Non-covalent bonds between histidine residues 
and nucleic acid may enhance the stability of siRNA polyplexes.  We first compared 
the polyplex biophysical properties of a branched HK with those of branched 
asparagine-lysine peptide (NK).  Consistent with siRNA silencing experiments, gel 
electrophoresis demonstrated that the HK/siRNA polyplex maintained its integrity 
with prolonged incubation in serum, whereas siRNA in complex with NK was 
degraded in a time-dependent manner.  Isothermal titration calorimetry of various 
peptides binding to siRNA at pH 7.3 showed that the initial binding of branched 
polylysine, interacted with siRNA was endothermic, whereas branched HK exhibited 
an exothermic reaction at initial binding.  The exothermic interaction indicates 
formation of non-ionic bonds between histidines and siRNA; purely electrostatic 




bond, we studied the protonation state of imidazole rings of a selectively 15N labeled 
branched HK by heteronuclear single quantum coherence NMR.  The cross-peaks of 
Nδ1-H tautomers of imidazole shifted downfield (in the direction of deprotonation) 
by 0.5 to 1.0 ppm with addition of siRNA, providing direct evidence that histidines 
formed hydrogen bonds with siRNA at physiological pH.  These results establish that 
histidine-rich peptides form hydrogen bonds with siRNA, thereby enhancing the 




Strategies involving siRNA provide the potential to manipulate gene expression and 
facilitate control of diseases.  One of the major hurdles in using siRNA or microRNA 
as therapeutic agents has been the lack of an efficient, stable, and safe delivery 
vehicle.  One means to prevent the degradation of nucleic acids by nucleases in the 
serum is to condense the nucleic acids with polycations.  By binding to the phosphate 
backbone of nucleic acids through electrostatic interactions, polycationic carriers 
neutralize their charges and forms polyplexes.  Compact forms of polyplexes 
significantly reduce the exposure of nucleic acids to serum, augment their half-life, 
and enable their greater penetration within the target tissue.  Consequently, polycation 
carriers such as liposomes, synthetic polymers, and cyclodextrins have shown 
considerable promise in delivering siRNA or DNA plasmids.  Although several 
promising non-viral polycation agents for gene delivery have been developed and 




Zuckerman et al. 2010; Strumberg, Schultheis et al. 2012), no siRNA carrier has been 
approved by the FDA for systemic delivery.   
 
To optimize delivery of siRNA by non-viral carriers, it is essential to understand the 
binding mechanisms and the biophysical properties of the carrier/siRNA complex.  
Correlating the factors that influence the compactness and stability of polyplexes with 
biological activity may help development of more effective carriers of siRNA.  
Fluorescent molecules such as ethidium bromide, acridine orange, and Hoechst dye 
have been used to study the binding affinity of polycations and siRNA or DNA 
plasmids, but binding exclusion assays with these dyes only examine binding affinity 
indirectly (Basu, Schwietert et al. 1990). Furthermore, free fluorescent molecules may 
interact with carriers and result in artifacts.  Isothermal titration calorimetry (ITC) has 
become an important technique for studying thermodynamics of protein-protein or 
protein-nucleic acid binding.  Quantitative analysis of thermodynamic parameters 
provides greater insight into the binding mechanism of carrier and nucleic acids 
(Utsuno and Uludag 2010; Zheng, Pavan et al. 2012).  In addition to ITC, nuclear 
magnetic resonance (NMR) spectroscopy can directly detect molecular interactions in 
biological solutions (Zuiderweg 2002), thereby providing a powerful and versatile 
technique for assessing peptide siRNA binding at the atomic level.  For example, 15N 
chemical shifts of the imidazole ring have been studied to elucidate hydrogen bonding 
interactions in serine protease (Bachovchin 1986; Farr-Jones, Wong et al. 1993), 
triosephosphate isomerase (Lodi and Knowles 1991), and a membrane component of 





Mixson’s lab is particularly interested in histidine-lysine (HK) peptide carriers (Fig. 
2.1) of siRNAs, which can effectively inhibited Raf-1 oncogene in tumor xenografts 
and reduce tumor growth by 60% (Leng and Mixson 2005; Leng, Scaria et al. 2005).  
Initially, in several laboratories including Mixson’s it was thought that formation of 
the HK polyplexes depended primarily on the electrostatic interaction of positively 
charged lysines with negatively charged phosphates and that the role of histidine was 
to buffer endosomes and aid release of nucleic acids (Midoux and Monsigny 1999; 
Chen, Zhang et al. 2001; Putnam, Gentry et al. 2001; Hatefi, Megeed et al. 2006; 
Kichler, Mason et al. 2006; Thiel, Hernandez et al. 2012).  In contrast to poly-L-
lysine (PLL) polyplexes, HK peptide in complex with plasmids is resistant to 
enzymatic degradation and provided high transfection efficiency (Zhang, Ambulos et 
al. 2004).  As a result, we hypothesized that histidines may play an important role in 
increased stability of polyplexes through non-ionic interactions, in addition to its role 
in buffering of endosomes. 
 
To explore types of non-covalent interactions other than Coulombic forces, a number 
of studies have examined binding behaviors between polymers and DNA (and/or 
RNA) in solutions with a range of salt concentrations by using ITC (Lohman, 
deHaseth et al. 1980; Mascotti and Lohman 1997; Prevette, Kodger et al. 2007).  On 
the basis of the counterion condensation theory (Manning 1969; Manning 1978), 
experiments at a range of salt concentration allow the contributions of non-




Lohman’s group has shown that a salt-dependent equilibrium constant is 
thermodynamically comparable for peptides containing lysine or arginine with the 
same net charge.  Nonetheless, compared with oligolysines, oligoarginines have more 
favorable enthalpic contributions to binding free energy, suggesting hydrogen bond 
formation between arginines and nucleic acids (Mascotti and Lohman 1997).  
Prevette and colleagues modeled their ITC data and calculated that the contribution to 
the free energy from non-electrostatic interaction of carbohydrates and DNA binding 
accounts for more than 60% of total free energy (Prevette, Kodger et al. 2007).  
Moreover, in a conformational study using circular dichroism, poly-L-histidine was 
shown to form complexes with DNA at elevated sodium chloride concentrations (2 
M) (Burckhardt, Zimmer et al. 1976), suggesting that non-ionic interactions may have 
a role in the complex formation.  More recently, investigators have used molecular 
dynamics to probe hydrogen bond formation and potential hydrogen bond 
donors/acceptors of carriers and DNA (Karatasos, Posocco et al. 2012; Kim, Afonin 
et al. 2013).  Although hydrogen bond formation between polymers and nucleic acids 
has been suggested by both salt-dependent thermodynamics and molecular modeling, 
direct evidence is lacking. 
 
The aim of this study was to investigate the role of histidine component of HK peptides 
in binding to siRNA.  We proposed that stable formation of the HK/siRNA polyplex, its 
resistance to serum, and its enhanced biological activity are the results of a combination 
of electrostatic and hydrogen-bond interactions.  The thermodynamic profiles of peptide 




of histidine-mediated hydrogen bonds, protonation of imidazoles was characterized using 
heteronuclear single quantum coherence (HSQC) NMR.  It is anticipated that 
consideration of those characteristics will radically reorient current procedures for 
evaluation of siRNA carriers.  
 
 
Fig. 2.1. Schematic structures and sequences of branched and linear peptides. 
Branched peptides are composed of a three-lysine core, with four branches attached at 
the four amino groups (N-terminal) of the core. The 20-mer linear H2K peptides have 
a sequence similar to a branch of H2K4b. The predominant repeating groups are 
underlined. Labeled histidines (U-15N3) and lysines (U-13C6 and U-15N2) are 







2.3 Materials and Methods 
 
2.3.1 Cell line 
Human malignant MDA-MB-435 cells were cultivated in Dulbecco’s minimal 
essential medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 20 
mM glutamine. Stable MDA-MB-435 cells expressing firefly luciferase were 
obtained by electroporation with a linearized pCpG-Luc plasmid and selection of a 
high expressing clone in the presence of genetecin (G418).  The pCpG-Luc vector 
was constructed by ligating the luciferase gene (digested from pMOD-Luc plasmid, 
InvivoGen, San Diego, CA) into the multiple cloning sites of pCpG-mcs (InvivoGen) 
as previously described (Leng, Scaria et al. 2006). 
 
2.3.2 siRNA 
The following siRNA sequences targeting luciferase were used: sense, 5’-CUG-CAC-
AAG-GCC-AUG-AAG-A-dTdT-3’; antisense, 5’-UCU-UCA-UGG-CCU-UGU-
GCA-G-dTdT-3’ (Thermo Scientific, Dharmacon Division, Lafayette, CO). For 
duplex annealing, each siRNA was maintained in siRNA buffer (Dharmacon) at room 





2.3.3 Synthesis and sequences of HK peptides 
The four-branched H3(+H)4b, N3K4b, and K4b peptides with predominant repeating 
groups -HHHK-, -NNNK- and -KKKK-, respectively, as well as the linear H2K (-
HHK-) and A2K (-AAK-) peptides (Fig. 2.1) were synthesized on a Rainin Voyager 
synthesizer (PTI, Tucson, AZ) by the biopolymer core facility at the University of 
Maryland Baltimore, as previously described (Leng and Mixson 2005).  
 
2.3.4 Peptide/siRNA polyplex preparation 
The peptides H3K(+H)4b, and N3K4b were mixed with equal volumes (37.5 µl) of 
siRNA (10 µg, 20 µM) and maintained at room temperature for 30 min. The resulting 
polyplexes were tested for stability in serum and/or silencing activity. The 
peptide/siRNA molar ratios (3/1 for H3K(+H)4b and 6/1 for N3K4b) were chosen 
based on the amounts needed for complete electrophoretic retardation of the 
polyplexes in the absence of serum (Chou, Leng et al. 2011). 
 
2.3.5 Stability of peptide/siRNA polyplexes in serum  
The stability of peptide/siRNA polyplexes was determined with gel electrophoresis.  
After the peptide/siRNA polyplexes formed at room temperature for 30 minutes, the 
resulting polyplexes (7.5 µl) were mixed with FBS (7.5 µl) and incubated at 37°C for 
0, 1, 4, 6, and 24 h. Each sample, containing 1 µg of siRNA (total volume 15 µl) was 




1), freshly formed polyplexes in the absence of serum (lane 2), and 50% FBS (lane 7) 
were also prepared as controls (Fig. 2.2). 
 
2.3.6 Gene silencing by peptide/siRNA polyplexes incubated with serum 
Luciferase-expressing MDA-MB-435 cells were plated in 24-well plates (0.5 ml of 
DMEM, 10% serum) 24 h before transfection at a density of 3×104 cells per well. 
The cells were then treated with H3K(+H)4b/siRNA or N3K4b/siRNA polyplexes (1 
µg siRNA/well) targeting luciferase that had been previously incubated in 50% FBS 
for 0, 4, or 24 h. Control (untreated) cells received 15 µl of DMEM/FBS (50%). 
Forty-eight hours after the addition of polyplexes, the cells were incubated with 200 
µl of lysis buffer (Promega, Madison, WI) followed by centrifugation at 13,000 g for 
5 min. After luciferase substrate (Promega) was added to the cell lysates, luciferase 
activity was measured by a Turner TD 20/20 luminometer (Promega). 
 
2.3.7 Isothermal titration calorimetry 
Peptides, and siRNA were dissolved in phosphate buffer (10 mM, pH 7.3).  
H3K(+H)4b was dissolved in 10 mM 2-(N-morpholino)ethanesulfonic acid (MES) 
buffer pH 5.0 and 6.0 for pH dependence experiments.  The thermodynamic profile of 
nucleic acid binding with HK peptides was obtained at 37°C with use of VP-ITC 
(MicroCal Inc., Northampton, MA).  The sample cell was filled with siRNA (1 µM, 
1.45 ml), and the syringe contained peptide solution (25 µM, 5 µl per injection). Each 




except the titration at pH 5 (2.5 µl/injection, 180 sec intervals, and a total of 117 
injections).  Heat of dilution was determined by titration of peptides into a buffer 
without siRNA.  Molar enthalpy and final figures were generated by Origin 5.0 
(OriginLab Corporation, Northampton, MA). 
 
2.3.8 NMR spectroscopy 
Heteronuclear Single Quantum Coherence (HSQC) NMR spectra were recorded at 23°C 
on a 600 MHz Bruker Avance III spectrometer (Bruker BioSpin, Billerica, MA) 
equipped with a cryoprobe TXI probe, and analyzed using NMRpipe (Delaglio, 
Grzesiek et al. 1995) and Sparky (UCSF).  The H3K(+H)4b peptide was selectively 
labeled with 15N or 13C as follows. In each terminal branch sequence 
KHHHKHHHKHHHKHHHK, the underlined histidines were uniformly labeled with 
U-15N3, and lysines were double labeled with U-13C6 and U-15N2 (Cambridge 
Isotopes, Cambridge, MA).  Sample buffer was either 10 mM phosphate buffer (pH 7.3; 
with or without 100 mM NaCl) or 10 mM MES buffer, pH 5.0, containing 5% D2O. 
For analysis of 15N relaxation data in the presence of siRNA, H3(+H)K4b:siRNA 
ratios of 10:1, 4:1, and 2:1 were selected. To determine the pKa of each histidine 
signal, HSQC spectra were obtained with 0.1 mM labeled H3K(+H)4b at pH values 
of  3.9, 4.4, 4.7, 5.1, 5.5, 5.9, 6.2, 6.5, 6.8, 7.2, and 7.9 in 10 mM phosphate-citrate 
buffer. This experiment specifically examined the amide protons on the imidazole 
ring.  A pH curve was developed with the proton and nitrogen chemical shifts at 









2.4.1 Stability of peptide/siRNA polyplexes in serum 
We first studied the stability of peptide/siRNA polyplexes in serum (50%) by gel 
electrophoresis.  Polyplexes are retarded in the well, and upon disruption of the 
polyplex, the siRNA can be released or degraded.  A four-branched HK, H3K(+H)4b 
(Fig. 2.1) was compared with a four-branched asparagine-lysine-rich peptide 
(N3K4b); degradation of naked siRNA in the presence of serum was used as a 
control.  The peptide/siRNA molar ratios (H3K(+H)4b, 3/1; N3K4b, 6/1) used in this 
study were selected because they provided complete retardation of siRNA (saturated 
binding).  The self-assembled polyplexes were incubated in FBS (50%) for 0, 1, 4, 6, 
and 24 h at 37°C, and then analyzed by gel electrophoresis.  To determine the band 
intensities and integrity of the polyplexes, the gels were pre-stained with ethidium 
bromide.  As seen in Fig. 2.2, H3K(+H)4b/siRNA polyplexes maintained their 
integrity for up to 24 h in the medium containing serum.  In contrast, the siRNA of 
N3K4b polyplexes was degraded in a time-dependent manner, with kinetics of 
degradation comparable to that of naked siRNA alone in serum.  This indicates that 
asparagine-lysine (NK) polyplexes were much more sensitive to serum exposure than 






Fig. 2.2. HK polyplexes showed resistance to dissociation and degradation by serum. 
siRNA in complex with H3K(+H)4b or N3K4b was incubated with 50% FBS at 37°C for 
the indicated times. Lanes are as follows: naked siRNA (1), polyplexes without serum 
(2), polyplexes with 1 h of serum incubation (3), 4 h (4), 6 h (5), 24 h (6), and 50% FBS 
without siRNA (7). For naked siRNA in the absence of peptide carriers, lanes 2 to 6 were 
the siRNA maintained in serum for 1, 2, 4, 6, and 24 h, respectively. Serum NA, serum 
nucleic acids (a faint band is visible in each lane on the original exposure). 
 
2.4.2 Luciferase silencing of serum incubated polyplexes 
We hypothesized that the stability of complexes would significantly affect the ability 
of peptide/siRNA polyplexes to silence target genes.  Polyplexes pre-incubated in 
serum for 4 or 24 h were examined for their ability to silence luciferase expressed by 
MDA-MB-435 cells.  In the absence of serum, H3K(+H)4b and N3K4b in complex 
with Luc siRNA inhibited luciferase expression by 90% and 50%, respectively (Fig. 
2.3).  The silencing activity of H3K(+H)4b/siRNA polyplexes was maintained even 
after 24 h of serum exposure, whereas silencing activity of serum incubated N3K4b 




Thus, biological activity of the polyplexes appears to correlate with their stability in 
serum, and HK polyplex is much more stable and effective than NK polyplex.  
 
 
Fig. 2.3. H3K(+H)4b polyplexes incubated with serum maintained high transfection 
efficiency. 
Prior to the transfection of MDA-MB-435 cells that stably express luciferase, 
H3K(+H)4b/siRNA and N3K4b/siRNA polyplexes were maintained at 37°C with 
serum (50%) for 0, 4, or 24 h.  While silencing of luciferase expression with 
H3K(+H)4b polyplexes was not affected by serum, silencing with N3K4b polyplexes 
was markedly reduced by incubation with serum. The data represent the mean ± SD 
of luciferase of six determinations for each treatment. *, P < 0.05; ***, P < 0.001. 
 
2.4.3 Thermodynamics of siRNA binding to branched peptides  
To study the different binding behaviors that presumably underlie the differences in 
stability of polyplex against nucleases in serum, we investigated peptide-siRNA binding 
using isothermal titration calorimetry (ITC).  The addition of H3K(+H)4b to siRNA (Fig. 
2.4) resulted in three peaks in the integrated enthalpy binding profile.  The initial 




stage, with siRNA in large excess, the interaction likely represents bimolecular binding of 
HK and siRNA with minimal formation of polyplexes.  The absence of siRNA 
polyplexes as detected by dynamic light scattering (DLS) at ratios corresponding to this 
initial phase further validates this hypothesis.  This initial enthalpy-driven binding of HK 
peptides to siRNA suggests the importance of non-ionic interactions, such as hydrogen 
bonding, stacking, or van der Waals interaction (Ross and Subramanian 1981). 
 
The initial phase was followed by two more transitions at HK peptide:siRNA molar 
ratios of 1.5 and 2.5: the second phase showed ΔH ~ -20 kcal/mol and the third was 
endothermic.  The transition from exothermic to endothermic binding was likely due 
to particle aggregation induced or permitted by charge neutralization of the siRNA 
phosphate backbone with HK peptides (Matulis, Rouzina et al. 2000).  The release of 
water and counterions upon aggregation apparently provides an entropic driving force 
for the interaction that compensate for its unfavorable endothermic enthalpy from 
electrostatic interaction (e.g., K4b with siRNA) (Mascotti and Lohman 1992; Matulis, 
Rouzina et al. 2000).  The aggregation was demonstrated by detection of polyplexes 
by DLS at peptide/siRNA molar ratios of 0.75 and 2.0, giving average particle size of 
247 and 1419 nm, respectively.  In contrast to binding of HK with siRNA, the initial 
binding of the branched K4b with siRNA showed an endothermic reaction (ΔH +35 
kcal/mole of injectant), indicative of purely entropy-driven electrostatic binding in 






Fig. 2.4. Isothermal titration calorimetry of peptide siRNA interaction. 
Representative isothermal titration calorimetry (ITC) raw data and integrated heat 
release for H3K(+H)4b, N3K4b and K4b peptides (0.12 molar ratio/injection) in 10 
mM phosphate buffer, pH 7.0.  Comparing H3K(+H)4b and N3K4b with K4b, 
histidine- and asparagine-containing peptides show exothermic binding at peptide 
siRNA molar ratios from 0 to 2.5, while K4b binding to siRNA is an endothermic 
reaction.  
 
Interestingly, asparagine-containing N3K4b siRNA interaction showed an enthalpy 
profile similar to that of H3K(+H)4b but at a reduced scale. Since the imidazole 
groups of histidines and amide groups of the asparagines can both function as 
hydrogen bond donors and acceptors, the formation of hydrogen bonds may play a 
major role in the exothermic binding at a peptide siRNA molar ratio of  0.1 to 1.0.  
The exothermicity for H3K(+H)4b binding with siRNA was 5 times greater than that 
for N3K4b.  This suggests that, H3K(+H)4b may have greater capacity to form 
hydrogen bonds with siRNA at physiological pH than N3K4b, thereby decreasing the 






Fig. 2.5. Linear peptides exhibit ITC profiles similar to the branched peptides. 
ITC profiles for linear peptides H2K and A2K (25 µM, 0.12 molar ratio/injection) 
titrated into siRNA (1 µM) were studied. Similar to branched peptides, histidine-
containing H2K show exothermic binding at molar ratio 0 to 1.5. In contrast, when 
histidines were replaced with alanines, A2K behaved similarly to K4b: only an 
endothermic reaction is observed.  
 
2.4.4 Independence of peptide structure to exothermicity 
 The effect of HK structures on thermodynamic profiles were then investigated.  We 
synthesized two linear peptides (20-mer): histidine-lysine-rich H2K and A2K, in 
which histidines were replaced with alanines.  ITC profiles of linear and branched 
HKs with siRNA were assessed to distinguish sequence-related results from the two 
types of polyplexes.  Similar to H3K(+H)4b, linear H2K showed a negative enthalpy 
change at low molar ratios, followed by a transition to an endothermic region (Fig. 




that of H3K(+H)4b, which contained four times more histidine.  In contrast, when the 
histidines were replaced with alanines, A2K showed endothermic binding with 
siRNA similar to that of K4b.  Thus, the effects of linear HK peptides parallel those 
of branched peptides, showing that the balance of ionic and non-ionic interaction is 
determined by local sequence, not branching patterns. 
 
2.4.5 pH dependence of binding 
At a pH lower than the pKa of imidazole groups, protonation of histidine residues 
increases.  ITC profiles obtained at pH 5 or 6 show a much smaller molar ratio of 
peptide:siRNA at saturation, indicating that the charge density per HK peptide was 
greatly increased at lower pH (Fig. 2.6).  Notably, with decreasing pH, the exothermic 
reaction was enhanced (pH 6.0, -90; pH 5.0, -120 kcal/mol) while the endothermic 
reaction was diminished.  Protonation of histidines potentially increases the number 
of hydrogen bond donors and thus increases the likelihood of hydrogen bond 
formation.  Nevertheless, the fully charged HK peptides may also avoid aggregation 
due to excess positive charges with electrostatic repulsion, which attenuated the 
rearrangement of small complexes formed in the first phase of binding (Fig. 2.7).  
Specifically, the thermodynamic profile of fully protonated H3K(+H)4b was in 
marked contrast with that of K4b (Fig. 2.4), indicating that the HK polyplexes formed 
at low pH were stabilized by non-electrostatic interactions, even though their charge 






Fig. 2.6. pH dependence of measured enthalpy of H3K(+H)4b siRNA binding. 
Representative ITC data for H3K(+H)4b addition to siRNA in 10 mM MES buffer, 
pH 6.0 and 5.0, are shown. With decreased pH and increased positive charge density 
of H3K(+H)4b, the amplitude of exothermic reaction was enhanced, while 
endothermic reaction was diminished.  
 
Fig. 2.7. Particle size measurement of H3K(+H)4b/siRNA titration 
The particle size of polyplexes while titrating the H3K(+H)4b to siRNA was 




2.4.6 NMR spectroscopy of free peptides and peptide/siRNA polyplexes 
To determine the type of non-ionic interaction that results in an enthalpy-driven 
binding of HK peptide with siRNA, we studied the protonation state of selectively 
15N-labeled histidines directly within H3K(+H)4b by using 1H-15N heteronuclear 
single quantum coherence (HSQC) NMR (Fig. 2.8). It has been shown that 15N 
chemical shifts of the imidazole ring are sensitive to hydrogen bond formation 
(Roberts, Chun et al. 1982; Bachovchin 1986; Van Dijk, Scheek et al. 1992; Farr-
Jones, Wong et al. 1993).  We recorded 1H-15N HSQC spectra of free HK peptides to 
measure J-coupling between two carbon-attached, non-exchangeable protons (Hε1 
and Hδ2) and two nitrogens of the imidazole ring (Nδ1 and Nε2) at pH values from 
3.9 to 7.9 (Fig. 2.9).  The three-bond 3JNδ1Hδ2 coupling results in a relatively weak 
cross-peak in HSQC spectra (Pelton, Torchia et al. 1993) whose intensities are 
diagnostic for histidine tautomer populations.  The chemical shifts of histidine 
nitrogens are classified with three possible protonation types: deprotonated, type-β 
nitrogen, 249.5 ppm; protonated, type-α nitrogen, 167.5 ppm; charged and 
protonated, type-α+ nitrogen, 176.5 ppm (Bachovchin 1986; Van Dijk, Scheek et al. 
1992; Pelton, Torchia et al. 1993).  At pH 7.3, the nitrogen protonation states 
identified two predominant tautomeric states of histidines among four labeled 
histidines.  The histidines that were more highly protonated were designated His 1, 
the other histidine signals His 2.   
 
The pH dependence of 1H chemical shift of Nε2-Hδ2 was then determined to 




equation.  A pH titration of the 1H and 15N chemical shifts of Nε2-Hδ2 was performed 
to obtain the pKa of each histidine signal, showing that His 1 and His 2 have pKa 
values of 6.3 and 5.3-5.8, respectively (Fig. 2.9).  Notably, His 1 differentiated into 
three individual cross peaks at low pH (Fig. 2.8 right panel).  Because of its repetitive 
sequence, however, we were not able to assign residue types to individual histidine 
residues.  Assuming the extent of proton transfer is linearly correlated to the 
difference of Nδ1 and Nε2 chemical shift, the tautomeric equilibrium of histidines 
can be quantified (Bachovchin 1986; Van Dijk, Scheek et al. 1992).  At pH 7.3, the 
protonation level of Nδ1 of His 1 and His 2 were 25% and 13.5%, and while at pH 
5.0, the protonation level of Nδ1 of His 1 and His 2 were increased to 35% and 20%, 
respectively. 
 
A titration of H3K(+H)4b by siRNA was also similarly monitored by 1H-15N HSQC 
spectra to determine whether peptide siRNA binding altered the tautomeric forms of 
His residues.  To increase the resolution and efficiency of signal acquisition, siRNA 
titration experiments were performed with a narrow sweep width (160 to 190 ppm, 
Fig. 2.8, middle and right pane).  Compared with the normal full-width spectrum, 
Nδ1-H signals of His 1 and 2 aliased by 36 ppm (negative phase, orange) and 72 ppm 
(positive phase, black) in the 15N dimension at pH 7.3, respectively. Upon the 
addition of siRNA, Nδ1-H of both histidines shifted downfield (towards the direction 
of deprotonation (Farr-Jones, Wong et al. 1993), (Fig. 2.10)) while the predominant  
Nε2-H remained unchanged. His 1 and 2 shifted by 0.5 to 1 ppm, respectively, at a 




buffer containing 100 mM NaCl (Fig. 10) demonstrating its nonionic in nature. The 
siRNA titration experiment shoed that as the peptide:siRNA molar ratio decreased to 
2:1 (data not shown), cross-peaks were broadened due to polyplex formation (Fig. 
2.10). The Nδ1 peak shifts induced by siRNA binding were enhanced by two fold (1-
2.5 ppm) at pH 5.0.  The perturbations of Nδ1 chemical shift of HK/siRNA 
polyplexes were positively correlated with the numbers of hydrogen bonds. Thus, the 
results of the HSQC are consistent with the thermodynamic behavior, which showed 







Fig. 2.8. Protonated nitrogen shifted toward the direction of deprotonation. 
Representative 1H-15N spectra (72 and 36 ppm, 15N width) of H3K(+H)4b (blue) at 
pH 7.3 (upper panel) and 5.0 (lower panel). Two imidazole ring sets of cross peaks 
were observed (His 1 and 2). siRNA was added at a peptide:siRNA molar ratio 4:1 
(red, right panel). The black and orange peaks at left and middle panels represent 
unfolded and folded peaks, respectively. Upon siRNA binding, both Nδ1-H tautomers
 
shifted downfield by 0.5 ppm at pH 7.3. The peak shift upon addition of siRNA 
demonstrates hydrogen bond formation. The complex-induced peak shift was 





Fig. 2.9. pH titration spectra and curves for the 15N-labeled histidine proton and 
nitrogen resonances in HSQC experiments. 
Representative 1H-15N spectra of free H3K(+H)4b at pH 3.9 (black), 5.1 (blue), 6.2 
(green), and 7.9 (red) is presented on the upper panel. The solid line (lower panel) 
represents the least-square fit of the data to the Henderson-Hasselbalch equation. pKa 
values of 6.3 and 5.8 for His 1 and His 2 were derived from proton resonance curve 









The binding mechanism and interaction between cationic polymers and siRNA are 
likely to have a critical role in the stability and delivery efficacy of the polyplexes.  
The goals of this work were to identify the contributions of purely ionic vs. non-
electrostatic interactions, to characterize hydrogen bonding patterns in the siRNA and 
peptides, and to identify the molecular origin of the enhanced stability and biological 
activity of the HK peptides. 
 
Fig. 2.10. NMR titration of H3K(+H)4b with siRNA. 
Representative 1H-15N spectra of free H3K(+H)4b and H3K(+H)4b/siRNA 
polyplexes at pH 7.3 (left), pH 5 (middle), and pH 7.3 buffer with added 100 mM 
NaCl (right). The colors represent several peptide/siRNA molar ratios of 13/1 (green), 
6/1 (black), and 4/1(red) or the “free peptide” (blue). As the amount of siRNA added 
to the peptides increased, the perturbation of Nδ1 resonance increased whereas Nε2 
remained unshifted.  
 
 
Polyplexes in which ionic interactions are dominant can be sensitive to physiological 
salt concentration and charged blood components such as albumin, thus reducing the 
ability to silence target genes in vitro and in vivo.  Serum destabilization of cationic 




charge ratio (Yang and Huang 1997), but excess polymers can be problematic for 
siRNA delivery.  For example, Mixson’s laboratory has demonstrated that higher HK 
to siRNA ratios are associated with poorly formed or small polyplexes that were less 
effective in gene silencing in vivo (Chou, Leng et al. 2011).  Moreover, an increased 
charge density of polycations may damage cell membranes, which results in 
cytotoxicity (Fischer, Li et al. 2003).  Nevertheless, the increased charge density of an 
ionizable polyplex upon protonation within acidic endosomes may lead to unpacking 
of the polyplexes with increased delivery of siRNA to the cytosol. 
 
In addition to electrostatic interactions, a number of studies have reported that non-
ionic interactions including hydrogen bonding may contribute significantly to binding 
of cationic carriers and DNA plasmids (Prevette, Kodger et al. 2007; Ma, Lavertu et 
al. 2009).  Hydrogen bond formation enhances the stability of polyplexes without the 
use of excess cationic polymers, thereby reducing cytotoxicity induced by excess 
positive charges.  Allen et al. have developed a hydroxyl-containing polymer in 
which intermediate binding and putative hydrogen bonding with DNA resulted in 
higher transfection (Allen, Green et al. 2011).  Hydrogen bond formation also plays a 
pivotal role in maintaining the condensed state of the polyplex in combination with 
electrostatic interactions, particularly when exposed to the disruptive effects of serum 
(Buyens, Meyer et al. 2010).  Despite the importance of hydrogen bonds in the 
stability of polyplexes, prior studies with histidine-containing polyplexes have 
focused on the role of histidine in buffering endosomes and not on its ability to 




intermolecular forces between HK peptides and siRNA by gel electrophoresis 
analysis, ITC, and NMR.  Together, the data indicate that hydrogen bonds formed 
between histidine residues and nucleic acids enhance the stability, silencing activity, 
and transfection efficacy of polyplexes.    
 
Isothermal titration calorimetry is a sensitive technique that has been used to 
determine the predominant factors critical for binding interactions. Previous studies 
have suggested that charge-charge interaction of polycations and nucleic acids is 
often accompanied by the depletion of counterions and the disruption of the hydration 
layer, greatly increasing entropy and driving an enthalpically unfavorable reaction 
(Matulis, Rouzina et al. 2000; Korolev, Berezhnoy et al. 2012).  In my data, 
exclusively entropy-driven binding was observed with the titration of K4b or A2K 
with siRNA, demonstrating that lysines interact primarily with negatively charged 
phosphate backbone of nucleic acids.  In contrast, peptides containing histidines, 
H3K(+H)4b or H2K, release a significant amount of heat in the initial phase of 
binding to siRNA.  This initial binding event probably represents a monomeric 
interaction between siRNA and HK peptide with minimal polyplex formation.  In 
contrast to the ionic interaction between K4b and siRNA, exothermic HK siRNA 
binding appears to be stabilized primarily by non-ionic interactions (Mascotti and 
Lohman 1997).  Furthermore, these non-ionic interactions were shown to be 
hydrogen bonds, as determined by diagnostic changes in NMR spectra under 





The transition from the exothermic to the endothermic phase of binding, as described 
in Results, was correlated with the aggregation of polyplexes.  The endothermicity is 
presumably due to strain energy or steric conflicts upon aggregation.  Similar 
thermodynamic results have been obtained for polyethylenimine binding to nucleic 
acids (Utsuno and Uludag 2010; Zheng, Pavan et al. 2012).  Polyplex formation is 
likely to involve multiple interactions, including ionic interaction, hydrogen bonding, 
π-π stacking, and/or hydrophobic interaction.  Interestingly, H3K(+H)4b and N3K4b 
shared similar binding patterns in which peptide siRNA interaction was initially an 
exothermic reaction, followed by two transitions.  Considering that both histidines 
and asparagines have amine groups compatible with formation of hydrogen bonds, it 
is anticipated that hydrogen bonding, rather than stacking, is the major source of 
exothermicity.   
 
Several studies have shown that the substitution of histidines with asparagines does 
not necessarily interrupt the binding and biological activity of proteins (Lowe, Fersht 
et al. 1985; Narayan, Chou et al. 2007).  However, the initial exothermicity of 
H3K(+H)4b binding to siRNA is 5 times greater than that of N3K4b (-80 vs. -15 
kcal/mole, Fig. 2.4) binding to siRNA.  The thermodynamic difference can be 
correlated with the serum stability of the polyplex determined by gel electrophoresis.  
The enthalpy of H3K(+H)4b siRNA initial binding is pH-dependent.  At pH 5.0, 6.0, 
and 7.3, the first exothermic peaks were -120, -90, and -80 kcal/mole, respectively. 
The results of HSQC also showed that Nδ1-H peaks of both histidines had a greater 




we assign to hydrogen bonding by histidines is enhanced by protonation to give 
HisH+, and protonation of histidine primarily enhanced the interactions of Nδ1-H 
protons with siRNA.  Furthermore, the hydrogen bond length of N-H donors of 
imidazole rings is generally shorter than N-H of amide groups on asparagines because 
of neighboring electron-withdrawing effects (Steiner 2002).  Thus, in addition to 
increased protonation level of Nδ1-H and charge potential, delocalization of electrons 
on the imidazole ring may also be responsible for the enhanced exothermic level, 
when siRNA binding of HK is compared with NK. 
 
Because unprotonated histidines serve as both hydrogen bond donors and acceptors, 
hydrogen bonds may not necessarily form between histidines and nucleic acids.  To 
determine the orientation of the hydrogen bond, we increased the protonation of 
histidines by lowering the pH to disrupt potential hydrogen bond interfaces of 
histidine-histidine (his-his) or histidine-lysine (his-lys) between HK peptides.  If his-
his or his-lys hydrogen bonding was dominant, protonation of histidines would 
decrease the number of hydrogen bond acceptors and therefore reduce hydrogen 
bonding and the exothermic level.  The enhanced exothermic interaction at lower pH 
(Fig. 2.6), however, provided evidence that hydrogen bond pairs were predominantly 
at the interface of H3K(+H)4b and siRNA.  Importantly, pH-dependent 
thermodynamic patterns correlated with the chemical shift perturbation in HSQC.  
Moreover, the addition of siRNA to H3(+H)4b gave rise to greater shift of Nδ1 peaks 
at lower pH as assessed with HSQC.  Whereas multiple lines of evidence indicate that 




and stabilizing the polyplex, the present studies do not support improved siRNA 
protection of siRNA by formation of his-his hydrogen bonds. 
 
 
Fig. 2.11. Isothermal titration calorimetry of H3K(+H)4b binding to DNA and 2’-
fluoro-siRNA. 
The binding of H3K(+H)4b to DNA resembles its binding to 2’-fluoro-siRNA. The 
initial binding saturates at a reduced rate until the first transition point compared with 
unmodified siRNA, suggesting that 2’-hydroxl groups play a role in hydrogen bond 
formation. 
 
The ITC data also shows that branched HK peptides have multiple binding stages 
upon titration into siRNA.  As previously described, the transition from exothermic to 
endothermic reaction is attributed to aggregation induced by the charge 
neutralization.  Nonetheless, the origin of the double peaks in the exothermic phase 




the siRNA with DNA oligonucleotides (Fig. 2.11), double exothermic peaks either 
regressed to one peak or became less significant.  Therefore, we speculate that the 
complicated binding patterns are correlated with charge heterogeneity in the branched 
structure of peptides and/or the response of the siRNA duplex.  Compared with DNA, 
dsRNA has narrow, deep major grooves and wide, shallow minor grooves, which 
differ in solvent accessibility.  The second stage of binding may be initiated when 
hydrogen bond donors and acceptors buried in the major groove are exposed to 
branched HK peptides once the binding sites in the minor groove are saturated or the 
A-form structure is altered by initial binding event. 
 
The HSQC spectroscopy established the involvement of histidines as potential 
hydrogen bond donors.  Although the current technique does not allow us to identify 
the exact hydrogen bonds involving building blocks on siRNA, a study has shown 
that phosphate oxygens, hydroxyl groups of riboses, and oxygens or nitrogens of 
nucleobases of nucleic acids provide potential hydrogen bonds acceptors to the side 
chain of histidines (Chen, Kortemme et al. 2004).  In a DNA- and RNA- binding 
protein-nucleic acids X-ray crystal structure database (Chen, Kortemme et al. 2004), 
the most common hydrogen bond acceptors are the phosphate oxygens.  When we 
replaced the siRNA with a 19-mer DNA with similar sequence, however, the 
thermodynamic profile of H3K(+H)4b and DNA binding showed reduced 
exothermicity ( initially -40 kcal/mol) and binding affinity.  Even though H3K(+H)4b 
does not bind specifically to double stranded RNA, the energetic difference between 




and/or 2’-hydroxyl groups also form hydrogen bonds (Schmedt, Green et al. 1995; 
Bevilacqua and Cech 1996).  In addition to DNA, a 2’-fluoro-modified siRNA was 
used to compare with unmodified siRNA binding to H3K(+H)4b to determine the 
role of 2’-hydroxyl groups.  The binding patterns of 2’-fluoro-modified siRNA was 
indistinguishable from DNA duplex (Fig. 2.11), suggesting that hydrogen bond 
formation between H3K(+H)4b and the 2’-hydroxyl groups of unmodified siRNA.  
We speculate that the polyplex is stabilized by hydrogen bond networks that occupy 
potential binding sites of ribonucleases or competing binding proteins.   
 
Both the ITC and HSQC data indicated that the overall contribution of hydrogen 
bonding increases at a pH below 7.3 (physiological), which leads us to explore how 
the siRNA escapes from polyplexes and endosomes.  With the pKa of histidines being 
6.3 or lower, we speculate that electrostatic repulsion between the histidines upon 
protonation in the acidic endosomes plays the dominant role in disrupting and/or 
unpacking the polyplexes (Fig. 2.12).  Furthermore, various charged proteins in the 
cytosol interacting with the loosely-packed HK polyplex may have a complementary 
role in promoting decomposition of polyplexes.  Unpacking of the polyplex could 
occur with further polyplex disruption into smaller and less dense smaller polyplexes, 
with monomeric HK siRNA units as part of the continuum.  Upon unpacking of the 
polyplex, regardless of the extent of disruption, the protonated HK peptides would 
likely interact with negatively charged endosomal membranes, which would thus act 
similarly to detergents to aid in the escape of siRNA.  This model is consistent with 




laboratory and others (Chen, Zhang et al. 2002; Rehman, Hoekstra et al. 2013).  
Moreover, if the electrostatic repulsion in the acidic endosomes disrupts polyplexes to 
the extent of releasing “free” peptide, the secondary structure of H3K(+H)4b may 
enhance the membrane lytic activity (Medina-Kauwe, Xie et al. 2005).  Accordingly, 
we propose a model in which the complexation of H3K(+H)4b and siRNA involves 
electrostatic interaction and hydrogen bonding, whereas decomplexation of 
polyplexes is induced by overcharging, disruption of the polyplex, and interaction of 
the peptide with the endosomal membranes (Fig. 2.12).  
 
 
Fig. 2.12.  Model of HK and siRNA binding illustrating compactness in serum and 
release (or partial release) in endosomes.  
The colors blue, green, and red represent positive, neutral, and negative electrostatic 
potential, respectively. Hydrogen bonds are shown as dashed lines. Scale bar in the 







Characterization of polyplex stability is considered one of the most important 
properties to understand for more effective carriers to be developed.  My study 
demonstrates that non-ionic interactions between HK peptides and siRNA is essential 
for increased stability of HK polyplexes in serum compared to polylysine polyplexes.  
In particular, spectral shifts in the NMR established that the histidine component of 
HK formed hydrogen bonds with siRNA.   Thus, in addition to the role of buffering 
endosomes by histidines, their formation of hydrogen-bonds with siRNA is likely a 
key reason why histidine-containing polyplexes are effective transfection and 
silencing agents.  Moreover, the distinguishing features derived from structural and 
biophysical studies with HK peptides may be shared by other hydrogen-forming 
peptides and synthetic polymers, even those without imidazole groups.  A 
fundamental understanding of vector-cargo interactions may establish evidence-based 





Chapter 3: Selective Modification of HK Peptides Enhances 




My research has focused on systemic delivery of small interference RNA (siRNA) by 
branched peptides composed of histidine and lysine, called HK peptides.  After 
studying several histidine-lysine (HK) peptides, one four-branched peptide, 
H3K(+H)4b, with a predominant repeating pattern of -HHHK-, was found to be an 
effective carrier of siRNA in vitro and in vivo.  Although the unmodified H3K(+H)4b 
carrier of siRNA targeting an oncogene was previously shown to have promise in a 
tumor-bearing mouse model, we sought to develop a more effective HK carrier of 
siRNA in the current study.  My primary goal was to determine whether different 
ligand (cyclic RGD)-PEGylation patterns on the H3K(+H)4b peptide affect siRNA 
delivery in vitro and in vivo.  We compared the unmodified H3K(+H)4b with two 
modified H3K(+H)4b peptides for their ability to deliver siRNA in a tumor-bearing 
mouse model; one modified HK peptide, (RGD-PEG)4H3K(+H)4b, had four cyclic 
RGD polyethylene glycol (cRGD-PEG) conjugates per molecule, whereas the other 
peptide, (RGD-PEG)H3K(+H)4b, had one cRGD-PEG per molecule.  Although the 
modified HK peptides by themselves did not form stable polyplexes with siRNA, 
combination of a highly charged unmodified HK peptide, H2K4b, with either of the 




with MDA-MB-435 cells that expressed luciferase, the H3K(+H)4b/siRNA 
polyplexes targeting luciferase decreased its activity by 90% compared with 
negligible down-regulation by the modified H3K(+H)4b polyplexes (P < 0.01).  In 
contrast, the two modified H3K(+H)4b/siRNA polyplexes administered intravenously 
were more effective than the H3K(+H)4b polyplexes in silencing luciferase in a 
tumor xenograft model.  The luciferase activity in tumor lysates of mice administered 
H3K(+H)4b, (RGD-PEG)H3K(+H)4b, and (RGD-PEG)4H3K(+H)4b polyplexes 
decreased by 18%, 35%, and 75%, respectively.  Thus, the siRNA polyplex 
incorporating the highly modified peptide, (RGD-PEG)4H3K(+H)4b, was the most 
effective at silencing its target in vivo (P < 0.01).  These studies demonstrate that 
selectively modified HK polymers are promising candidates for targeting oncogenes 




RNAi is a promising research and therapeutic strategy, utilized to down-regulate 
aberrant disease-causing genes and to study genes important for signal transduction 
pathways.  The RNAi process is activated by incorporation of a 19 to 23-mer double 
stranded RNA fragment (siRNA) into the RISC complex (Fire, Xu et al. 1998).  
Together with the Argonaut 2 endonuclease that is part of the RISC complex, the 
siRNA recognizes and cleaves the target mRNA in a catalytic manner (Hammond, 




Reynolds, Leake et al. 2004).  To realize the potential of siRNA as a therapeutic 
agent, an effective delivery system for siRNA is essential to facilitate specific 
targeting and cellular uptake in the target tissue, particularly for systemic diseases 
such as cancer.  Indeed, the development of an efficient delivery system for nucleic 
acids including siRNA has proved elusive and has been the rate-limiting step in 
developing siRNA-based therapeutics.   
 
Nevertheless, there are many promising carriers for siRNA in various stages of pre-
clinical and clinical trials, including synthetic polymers, aptamers, neutral and 
cationic liposomes, and peptides (Schiffelers, Ansari et al. 2004; Morrissey, 
Lockridge et al. 2005; Song, Zhu et al. 2005; Bartlett and Davis 2008; Kim, Jeong et 
al. 2008; Merritt, Lin et al. 2008; Peer, Park et al. 2008; Dassie, Liu et al. 2009; Mu, 
Nagahara et al. 2009).  Currently, no systemic carrier of siRNA has fully been proven 
effective for clinical use against cancer, but evidence points to a need for ligand-
mediated tissue targeting and a preference for polyplex forms.  Moreover, it is likely 
that non-viral carriers will continue to evolve for the foreseeable future, with 
progressive improvements.  To this end, Mixson’s lab has focused on developing an 
effective in vitro and in vivo vehicle for small interference RNA.  To accomplish this, 
we have synthesized and screened a number of histidine-lysine rich peptides 
(HK)(Chen, Zhang et al. 2001; Chen, Zhang et al. 2002; Leng and Mixson 2005; 
Leng, Scaria et al. 2005) testing their ability to carry and deliver siRNA to give 
effective gene inhibition.  While lysines are essential for binding siRNA, histidines 




Altering the sequence of histidines and lysines within the branches of the HK 
polymer can affect its ability to transport siRNA within the cell.  After studying 
several HK peptides, one 4-branched form, H3K(+H)4b, with predominant repeating 
patterns of -HHHK-, was determined to be an effective carrier of siRNA; the 
H3K(+H)4b/siRNA polyplexes targeting the Raf-1 oncogene inhibited tumor growth 
by 60% (Leng, Scaria et al. 2008). 
 
In the current study, we sought to develop a more effective ligand targeted form of 
the H3K(+H)4b/siRNA polyplex, particularly for use in vivo.  In order to prevent 
aggregation and to selectively target the tumor with the polyparticle, the H3K(+H)4b 
was modified by varying the number and location of cRGD-PEG conjugates.   Two 
modifications of H3K(+H)4b were made: one highly modified HK polymer in which 
an cRGD-PEG was attached to each branch (four cRGD-PEG per molecule) and the 
other, a more limited HK modification in which the cRGD-PEG was attached to the 
(Lys)3 core that generates the branched polypeptide (one cRGD-PEG per molecule).  
Compared to the unmodified H3K(+H)4b, both modified HK peptides when 
combined with an unmodified HK peptide were markedly more effective carriers of 
siRNA to tumors in a murine model.  Moreover, the siRNA polyplex containing the 








3.3 Materials and Methods 
 
3.3.1 Animals 
Female athymic mice (4-8 wk old) were purchased from NCI (Frederick, MD). The 
experiments were done in accordance with regulations by the Institutional Animal 
Care and Use Committee of the University of Maryland Baltimore. 
 
3.3.2 Cell line 
A human malignant cell line MDA-MB-435, stably expressing Firefly luciferase, was 
cultured in Dulbecco’s minimal essential medium (DMEM) containing 10% fetal calf 
serum (FCS) and 20 mM glutamine.  
 
3.3.3 Synthesis, sequences, and chemical modification of HK peptides 
The branched HK polymer was synthesized on a Rainin Voyager synthesizer (PTI, 
Tucson, AZ) by the biopolymer core facility at the University of Maryland, as 
previously described.  The unmodified four branched H3K(+H)4b and H2K4b 
polymers, with  dominant repeating patterns of -HHHK- and -HHK-, respectively, 
were synthesized as described previously (Leng, Scaria et al. 2005).  The four 
terminal branches of the HK polymers emanate from the 3-lysine core: for 
H3K(+H)4b, the branch sequence is KHHHKHHHKHHHHKHHHK and for H2K4b, 




H3K(+H)4b, a cysteine was added to each of the four N-terminal branches or to the 
C-terminal end of the lysine core.  Cyclic (c)RGD-PEG  was conjugated to the HK 
polymer using a synthesis procedure similar to one previously described (Schiffelers, 
Ansari et al. 2004).  Briefly, cyclic RGD peptide with the sequence c(RGDfK) 
(purchased from Peptides International, Louisville, KY) was coupled to 3.4 kD PEG 
using a heterobifunctional PEG, SCM-PEG-VS, from Nektar Therapeutics 
(Huntsville, AL), in dry DMSO in equimolar ratio. The cRGD-PEG conjugate was 
precipitated from DMSO by adding 10 fold excess of anhydrous cold ether. The 
resulting solid material was dried, characterized and used for coupling to 
H3K(+H)4b. The cRGD-PEG-VS conjugate obtained was then reacted with 
H3K(+H)4b consisting of cysteine at the N-terminus of each of the four branches (for 
(RGD-PEG)4-H3K(+H)4b) or C-terminus (for (RGD-PEG)H3K(+H)4b ) at pH 7.3 
(HEPES buffer), to obtain the cRGD-PEG modified polypeptides. The modified 
H3K(+H)4b peptides were purified by dialysis and characterized by amino acid 
analysis.  The resulting conjugates on average had one (for (RGD-PEG)H3K(+H)4b) 
or four (for (RGD-PEG)4H3K(+H)4b)) cRDG-PEG moieties, based on amino acid 
analysis of the purified conjugates. 
 
3.3.4 siRNA 
The siRNA duplex targeting luciferase (Luc) was as follow: sense, 5’-CUG-CAC- 
AAG-GCC-AUG-AAG-A-dTdT-3’; antisense, 5’-UCU-UCA-UGG-CCU-UGU-
GCA-G-dTdT-3’, targeting 5’-CUG-CAC-AAG-GCC-AUG-AAG-A-3’.  The 2-O-




except that the uridines in the sense strand had 2-OMe modifications.  The control 
siRNA was siGENOME Non-Targeting siRNA #3, sense 5’-AUG-UAU-UGG-CCU-
GUA-UUA-G-dTdT-3’; antisense, 5’-CUA-AUA-CAG-GCC-AAU-ACA-C-dTdT-3’ 
(Dharmacon, Lafayette, CO).      
 
3.3.5 Gel retardation assay 
The amount of HK polymer (modified and/or unmodified) to neutralize siRNA was 
determined by the gel retardation assay.  Varying amounts of HK peptides were 
mixed with 1 µg of siRNA and incubated for 30 minutes at room temperature.  
Specifically, the following HK:siRNA ratios (w/w or w/w/w) were prepared in water: 
1) H3K(+H)4b:siRNA (1:1; 1.5:1; 2:1; 2.2:1; 2.5:1); 2) (RGD-
PEG)H3K(+H)4b/H2K4b:siRNA and 3) (RGD-PEG)4H3K(+H)4b)/H2K4b:siRNA 
(3/0.6:1; 4/0.6:1; 6/0.6:1; 3/0.8:1; 4/0.8:1; 6/0.8:1).  After the HK/siRNA polyplex 
was loaded onto the gel (3 % agarose), electrophoresis was carried out at a constant 
voltage of 75 V for 45 minutes in TBE buffer containing ethidium bromide.  The 
siRNA band densities were then visualized under a UV transilluminator at a 
wavelength of 365 nm.  On the basis of fluorescence (UN-SCAN-IT; Silk Scientific, 
Orem, UT) of siRNA that had migrated into each lane, the stability of HK/siRNA 
polyplex was determined.  A gel retardation assay was also done on each in vivo HK 
siRNA preparation injected into the mice.  Gel retardation assays similar to those 
described above were also carried out with HK polyplexes after exposing them to 





3.3.6 Particle size and surface charge analysis 
Particle size was measured on all HK polyplexes by dynamic light scattering (DLS) 
with the N4 plus particle size analyzer on HK polyplexes (Beckman Coulter Corp., 
Miami, FL).  The zeta potential was measured by Delsa 440 SX instrument (Coulter) 
on HK/siRNA polyplexes that were used for in vivo studies.   
 
3.3.7 HK siRNA nanoparticle preparation 
For in vitro experiments, HK/siRNA polyplexes were prepared as previously 
described (Leng, Scaria et al. 2005; Leng, Scaria et al. 2008) by briefly mixing 
siRNA (1 µg) in 50 µl of OptiMEM (Invirtrogen, Carlsbad, CA) with various 
amounts of HK peptides.  The siRNA polyplexes were maintained at room 
temperature for 30 min prior to size measurements and/or incubation with cells or 
serum.  The ratios for HK to siRNA were based on gel retardation assays with 
additional ratios tested for in vitro bioluminescent assays.  
 
For tumor xenografts experiments in vivo, mice were treated by injection in the tail 
vein with HK polyplexes containing 40 µg of luciferase or control siRNA.  After the 
polymers were mixed with the siRNA, the resulting polyplex formed at room 
temperature for 40 minutes.  Each mouse was then treated by i.v. injection with 300 
µl of the polyplexes.  The ratios of polymers to siRNA for in vivo bioluminescent 





3.3.8 Stability of HK polyplexes in serum 
With one microgram of siRNA in complex with the optimal amount of unmodified 
H3K(+H)4b or the two modified cRGD-PEG H3K(+H)4b peptides, the polyplexes (2 
ml) were incubated with increasing concentrations (0%, 10%, 50% and 75%) of 
mouse serum (total  volume 10 µl) for 1 h at room temperature.  The gel retardation 
assay was used to test the stability of the polyplexes in serum.   
 
3.3.9 Cellular uptake 
Cells (1 × 105) were incubated with different carriers (H3K(+H)4b, (RGD-PEG)-
H3K(+H)4b/H2K4b, or (RGD-PEG)4H3K(+H)4b/H2K4b) in complex with Cy3 
labeled-siRNA (IDT, Coralville, IA).  After 4 h, cells were fixed in formaldehyde for 
5 min; the nuclei were stained with chromatin dye Hoechst 33342 (Invitrogen, 
Carlsbad, CA) in PBS for 5 min.  Confocal images were obtained with a Zeiss 
LSM510 laser scanning confocal microscope (Carl Zeiss, Thornwood, NY).  
 
3.3.10 In vitro bioluminescence assays 
MDA-MB-435 cells expressing luciferase were plated in a 24-well plate (0.5 ml of 
DMEM, 10% serum) at a density of 3 × 104 cells/well.  Various peptides and peptide 
combinations (H3K(+H)4b, (RGD-PEG)H3K(+H)4b, (RGD-PEG)4H3K(+H)4b, 
(RGD-PEG)H3K(+H)4b/H2K4b, and (RGD-PEG)4H3K(+H)4b/H2K4b, in complex 
with Luc-siRNA (1 µg), were prepared as described previously, and polyplexes were 




tested for in vitro bioluminescent experiments were as follows: H3K(+H)4b:siRNA, 
2.2:1, 4:1, 6:1;  (RGD-PEG)H3K(+H)4b:siRNA, 2:1, 4:1, 6:1; (RGD-PEG)4-
H3K(+H)4b:siRNA, 2:1, 4:1, 6:1; (RGD-PEG)H3K(+H)4b/H2K4b:siRNA, 2/0.8:1, 
3/0.8:1; 6/0.8:1; (RGD-PEG)4H3K(+H)4b/H2K4b:siRNA, 2/0.8:1, 4/0.8:1, 
6/0.8:1.The cells were then exposed to lysis buffer (200 µl) (Promega, Madison, WI) 
followed by centrifugation at 12,500 rpm for 5 min.  The luciferase activities in the 
supernatant fraction were measured by a Turner TD 20/20 luminometer (Promega). 
 
3.3.11 In vivo bioluminescence experiments 
a. Tumor lysates:  MDA-MB-435 xenografts that stably expressed luciferase 
were established by injecting 2 x 106 cells into midclavicular line of female 
nude mice (NCI Frederick).  After tumor reached about 50 mm3, mice were 
separated into five treatment groups: untreated, H3K(+H)4b/Luc siRNA 
(w/w, 2.2/1), (RGD-PEG)H3K(+H)4b/H2K4b/Luc siRNA (w/w/w, 3/0.8/1), 
and (RGD-PEG)4H3K(+H)4b/H2K4b/Luc siRNA or control siRNA (w/w/w, 
4/0.8/1).  These HK polyplexes containing 40 µg of siRNA were 
administered via the tail veins.  Forty-eight hours after inoculation of the 
polyplexes, the mice were euthanized and luciferase activity was then 
measured in tumor homogenates.  After determining the most effective 
carrier, time course and 2’OMeLuc siRNA experiments were performed in a 
similar manner.  Tumor volume was determined using the formula 1/ 2 × 
length × width2.   




HK/siRNA polyplexes in tumor- bearing mice was similar to tumor lysate 
experiments except that the IVIS-200 optical imaging system (Xenogen 
Corp., Almeda, CA) measured tumor luciferase activity in real-time in living 
mice.  At the time of imaging, mice were anesthetized with a 2.5% 
isofluorane/oxygen mixture and injected i.p. with 150 mg/kg of D-Luciferin 
(Caliper LifeSciences, Hopkinton, MA); photon emission was measured 15 
min after the administration of luciferin.  To standardize the photon emission 
(i.e., RLU), the region of interest at times 0 and 48 h were of equal size.     
 
3.3.12 Cytokine measurements 
A multiplex bead-based assay using Luminex technology was used to measure serum 
levels of mouse INF-α, INF-γ, TNF-α, and IL-6 as described by manufacturer 
(Upstate Waltham, MA).  Levels of mouse INF-α were measured with an ELISA kit 
as described by the manufacturer (PBL Biochemical Laboratories, Piscataway, NJ).  
These assays were done by the cytokine core facility at the University of Maryland 
School of Medicine. 
 
3.3.13 Statistics 
Since the number of observation is too small to be assumed a normal distribution, 
results comparing multiple groups were analyzed by Kruskal Wallis one-way analysis 
of variance on ranks (GraphPad Prism 6.0, La Jolla, CA).  Wilcoxon rank-sum test 




means, and error bars represent standard deviation.  In all cases, differences were 




3.4.1 Optimization of HK/siRNA polyplexes 
To determine appropriate HK and siRNA ratios for in vivo studies, gel retardation 
assays (Kim, Jeong et al. 2006; Huh, Lee et al. 2010; Ofek, Fischer et al. 2010) and 
particle size measurements using dynamic light scattering (DLS) were used to 
facilitate development of siRNA polyplexes.  Moreover, we have previously found 
that plasmid polyplexes formed with HK peptides that were approximately 100 to 150 
nm in size were effective in transfection of tumor xenografts (Leng, Scaria et al. 
2006).  Therefore, we examined various ratios of HK to siRNA to determine the 
minimal amount of HK that would form polyplexes retaining approximately 90% or 
more of the siRNA in the loading well and that would result in a polyplex with a 
diameter of 150 nm or less (Fig. 3.1).  For H3K(+H)4b, the lowest ratio to retard 
siRNA and still be associated with the smallest particle size was 2.2/1 (w/w) (ratio, 
4/1).  At this ratio, about 92% of the siRNA was retarded and the size of the siRNA 
polyplex was 149 ± 41 nm.  In contrast to the unmodified H3K(+H)4b, both modified 
HK were unable to retard siRNA, even at very high ratios (i.e., 7/1, N/P).  Moreover, 
at any ratio of the modified HK polymers to siRNA, the particle size of the siRNA 




combined an unmodified H2K4b peptide that has a high lysine content and greater 
condensing properties with the modified H3K(+H)4b polymers to enable greater 
siRNA binding.  For the modified polymer with only one cRGD-PEG conjugated to 
its core, the optimal (RGD-PEG)H3K(+H)4b/H2K4b/siRNA ratio was 3/0.8/1 
(w/w/w; N/N/P ratio, 4/1/1); this ratio resulted in 99% retardation of the siRNA and a 
nanoparticle size of 147±51 nm.  For the highly modified HK, the selected (RGD-
PEG)4H3K(+H)4b/H2K4b/siRNA ratio was 4/0.8/1 (w/w/w; N/N/P ratio 3/1/1), the 
minimum amount of HK polymer to produce a stable polyplex.  These selected ratios 
for unmodified and modified polymers to siRNA were used in subsequent 
experiments although additional ratios were also evaluated for in vitro gene silencing 
experiments.  At these selected ratios, polyplexes containing the H3K(+H)4b, (RGD-
PEG)H3K(+H)4b, and (RGD-PEG)4H3K(+H)4b had zeta potentials of 37, 17.3, and 
16.7 mV, respectively.  Notably, the amount of H2K4b used in siRNA polyplexes 
that also incorporated modified H3K(+H)4b was not sufficient to neutralize the 
negatively charged siRNA; the H2K4b/siRNA ratio of 0.8/1 (w/w) retained only 35% 
of the siRNA in the gel retardation assay (data not shown).   
 
3.4.2 In vitro evaluation of HK peptides as carriers of siRNA 
We also tested the ability of unmodified and modified HK/siRNA polyplexes to 
down- regulate luciferase stably expressed in MDA-MB-435 cells.  Of note, MDA-
MBA-435 cells have elevated levels of the αvβ3 integrin, the receptor for cRGD 
(Felding-Habermann, O'Toole et al. 2001).  The unmodified H3K(+H)4b or the two 




targeting siRNA in vitro.  Unmodified H3K(+H)4b polyplexes inhibited luciferase 
activity by approximately 90%, while the polyplexes containing only modified HK 
peptides had minimal activity (Fig. 3.2A).  In addition, the polyplexes with the 
modified HK combined with H2K4b had no activity across several HK:siRNA ratios.  
These functional siRNA assays correlated with fluorescent uptake studies.  That is, 
significant numbers of large intracellular particles from the unmodified 
H3K(+H)4b/siRNA polyplexes accumulated intracellularly after four hour of 
incubation while the modified HK/siRNA polyplexes showed a diffuse fluorescence 
pattern similar to the siRNA control (Fig. 3.2B).  Similar fluorescence patterns were 
observed at different time points (data not shown). 
 
Fig. 3.1. Gel retardation assay 
To determine the amount of HK that retards siRNA migration, various ratios of 
unmodified H3K(+H)4b (A) or modified HK combinations (B, (RGD-PEG)-
H3K(+H)4b/H2K4b; C, (RGD-PEG)4H3K(+H)4b/H2K4b) in complex with siRNA (1 
µg) were prepared and then subjected to gel electrophoresis for 30 minutes (3% gel).  
Different ratios of HK polymers to siRNA are represented above the gel and the 
particle size is shown below the gel.  For the modified HK groups (b,c), modified and 
unmodified polymers (H2K4b) were mixed for more complete retardation of siRNA. 
The ratio enclosed in the box represents the selected in vitro and in vivo silencing 
conditions based on the size of the particle (less than 150 nm) and siRNA retardation.  
NA represents polyplexes in which the size could not be determined by dynamic light 







Fig. 3.2. In vitro comparison of HK polymers as carriers of siRNA 
(A) Several HK or combination of HK carriers (H3K(+H)4b, (RGD-
PEG)H3K(+H)4b, (RGD-PEG)4H3K(+H)4b, (RGD-PEG)H3K(+H)4b/H2K4b, 
(RGD-PEG)4H3K(+H)4b/H2K4b) of Luc siRNA were tested for their abilities to 
inhibit luciferase expression in MDA-MB-435 cells compared with the untreated 
group. H3K(+H)4b was the most effective carrier down- regulating expression by 
nearly 90%, whereas inhibition by other carriers was negligible.  The data represent 
the mean ± SD of luciferase of six determinations for each carrier.  **, P < 0.01; 
H3K(+H)4b vs. modified HK carriers. (B) Comparison of uptake of different 
HK/siRNA polyplexes.  A number of discrete intracellular fluorescent particles of 
siRNA were observed with unmodified H3K(+H)4b carriers, whereas the 
combination of modified and unmodified HK/siRNA polyplexes showed diffuse 
intracellular fluorescence- similar to the fluorescence pattern observed with the 
siRNA alone.  Images were obtained by a Zeiss LSM510 laser scanning confocal 
microscope.  The HK to siRNA ratios were as follows:  H3K(+H)4b:siRNA, 4:1;  
(RGD-PEG)H3K(+H)4b, 4:1; (RGD-PEG)4H3K(+H)4b, 4:1; (RGD-PEG)-
H3K(+H)4b/H2K4b, 3/0.8:1; (RGD-PEG)4H3K(+H)4b/H2K4b, 4/0.8:1.   
 
3.4.3 In vivo evaluation of HK peptides as carriers of siRNA 
Similar to the in vitro study, we screened numerous HK polymers in complex with 
Luc siRNA for their ability to inhibit luciferase in tumor xenografts.  After MDA-
MB-435 tumors expressing luciferase grew to approximately 50 mm3, the mice were 




Luc siRNA polyplexes.  After 48 h, the mice were euthanized and the tumor lysates 
were evaluated for luciferase activity.  The group treated with (RGD-
PEG)4H3K(+H)4b/H2K4b in complex with Luc siRNA was the most effective in 
silencing the tumor luciferase activity (Fig. 3.3), with activity reduced by about 75% 
(P < 0.01; (RGD-PEG)4H3K(+H)4b/H2K4b vs. other carriers and control groups).  
The unmodified H3K(+H)4b and (RGD-PEG)H3K(+H)4b/H2K4b polyplexes 
reduced tumor luciferase activity by 18 and 35%, respectively (P < 0.05; (RGD-
PEG)-H3K(+H)4b/H2K4b vs. unmodified H3K(+H)4b or untreated).  Thus, the 
highly modified HK polyplex formulation was the most effective.  To determine 
whether reduction of tumor luciferase was based on the specificity of the siRNA 
mechanism, a non-targeting siRNA in complex to the most effective carrier, (RGD-
PEG)4H3K(+H)4b/H2K4b, was used as the negative control in vivo.  There was 
approximately 20% inhibition for the non-targeting siRNA polyplex, suggesting that 





Fig. 3.3. In vivo evaluation of HK polymers to determine most effective carrier for 
Luc-siRNA   
Four HK siRNA preparations (three HK-Luc siRNA; one HK-control siRNA) were 
compared for their ability to silence luciferase expression in MDA-MB-435 xenografts.  
The modified HK peptide, (RGD-PEG)4H3K(+H)4b/H2K4b, of Luc siRNA was the most 
effective, reducing luciferase expression in tumor xenografts by 75%.  HK:siRNA ratios 
used in this experiment were chosen based on the gel retardation assays.  The data 
represent the mean ± SD of luciferase of six determinations for each carrier.  *, P < 0.05; 
(RGD-PEG)4H3K(+H)4b/H2K4b carrier vs. other carriers and control groups. 
 
We also confirmed the tumor lysate studies with the Xenogen optical imaging system 
and demonstrated that highly modified H3K(+H)4b polyplexes significantly 
suppressed luciferase activity in tumor xenografts (Fig. 3.4).  Mice treated with the 
highly modified H3K(+H)4b/H2K4b combination in complex with Luc-siRNA had 
decreased luciferase activity in tumors of 63 ± 15% compared to luciferase activity of 




±1.71×105 at time 0, and 9.43 ± 2.33 ×105 48 h later, whereas for treated mice, the 
RLU was 7.78 ± 1.90 ×105 at time 0, and 3.08 ± 0.59 ×105 at 48 h.  The regions of 
interest at time 0 and 48 h for RLU determinations were equal in size. 
 
Fig. 3.4. Bioluminescence imaging 
Bioluminescence imaging was performed with the Xenogen IVIS 200 system.  Mice 
bearing tumor xenografts were separated into two groups after the tumor size reached 
50 mm3 and this experiment was repeated three times.  (A) and (B) show tumor 
images of representative mice taken before treatment and 48 h after treatment, 
respectively.  The mouse on the right in (A) and (B) was untreated; the mouse on the 
left of (A) and (B) was treated with (RGD-PEG)4H3K(+H)4b/H2K4b/Luc siRNA 
polyplex (designated HK/Luc siRNA) by tail vein injection.  The mouse treated with 
siRNA showed a marked down-regulation of luciferase.  (C) This shows the mean of 
the experiments comparing untreated mice with treated mice (n=3).  In mice treated 
with luciferase siRNA, luciferase activity was reduced by 63.14 ± 15.18%.  **, P = 
0.01; siRNA treated vs. untreated.   
 
3.4.4 Time course of siRNA-mediated luciferase inhibition in vivo 
To determine the duration of Luc silencing in the MDA-MB-435 xenografts, a time 
course was done with the most effective polyplex, (RGD-PEG)4-
H3K(+H)4b/H2K4b/Luc siRNA.  After HK/siRNA polyplex injection, inhibition of 
luciferase activity was 71% at 24 h, 75% at 48 h, and 46% at 72 h compared to 




dosing may be about 3 days for rapidly dividing tumor cells to obtain maximum 
tumor growth inhibition (Bartlett and Davis 2006; Bartlett, Su et al. 2007; Bartlett and 
Davis 2008).   
 
 
Fig. 3.5. Time course of siRNA induced luciferase activity reduction 
Tumor-bearing mice were injected with the optimal HK/Luc siRNA polyplex and 
luciferase activity was determined from tumor lysates at 24, 48, or 72 h.  Compared to 
activity before treatment, luciferase activity was down-regulated by 71%, 75% and 
46% at 24 h, 48 h, and 72 h respectively.  *, P < 0.05; 72 h vs. 24 and 48 h time point.  
The data for each time point represent the mean ± SD of luciferase. 
 
3.4.5 Cytokine induction by HK/siRNA polyplexes  
Cationic carriers in complex with siRNA can induce cytokines which in turn                                                                                                                                                       
can result in cellular toxicity and/or inhibit gene expression in tumors by an indirect 
mechanism (Hornung, Guenthner-Biller et al. 2005; Judge, Sood et al. 2005; Kim, 
Choung et al. 2007; Zamanian-Daryoush, Marques et al. 2008).  Thus, luciferase 




apoptosis, non-specific mechanisms other than siRNA-mediated gene silencing.  To 
minimize cytokine induction by the siRNA polyplex in vivo, the sense strand of the 
siRNA can be modified by cautious addition of a methyl group to the 2’-hydroxyl 
group of the ribose without significantly affecting the biological activity of the siRNA 
(Robbins, Judge et al. 2007).  In (RGD-PEG)4H3K(+H)4b/H2K4b polyplexes, a 2’O-
methylated Luc siRNA was compared to unmodified Luc siRNA.  If cytokine 
induction resulted in a non-specific cytotoxic effect from the polyplexes, then the 
unmodified siRNA polyplex would likely be more effective at reducing luciferase 
activity compared to the 2’-OMe luciferase polyplex.  As shown in Fig. 3.6A, 
however, there were no significant differences between the unmodified and 2’-OMe 
siRNA tumor-bearing treatment groups; the decrease in luciferase activity was 80% 
in the 2’-OMe siRNA group vs. 75% in the unmodified siRNA group.  Furthermore, 
the HK in complex with siRNA (unmodified or 2’-OMe modified) did not induce 
higher cytokine levels (IL-6, INF- α, INF-γ, and TNF-α) compared to the untreated 
groups (Fig. 3.6B).  The cytokine levels in three groups were very low in comparison 
to DOTAP liposomal siRNA complexes, particularly for INF-α (INF-α, 754 pg/ml).  
Together, these data indicate that modified HK/siRNA polyplexes administered i.v. 
did not increase the level of cytokines in mice and cytokine induction by the 
HK/siRNA polyplex did not have a significant role in decreased expression of 








Fig. 3.6. Effect of induced cytokines on luciferase activity. 
(A) Unmodified and 2’OMeLuc siRNA in complex with the optimal HK combination 
were compared for their ability to reduce luciferase activity in tumor xenografts.  The 
reduction in luciferase activity was similar in the two groups (75% with unmodified 
vs. 80% with 2’OMeLuc siRNA), indicating that silencing was not due to induction 
of cytokines.  The data represent the mean ± SD of luciferase activity of five 
determinations for each carrier. **, P < 0.01; siRNA treated vs. untreated.  (B) Serum 
cytokine levels in MDA-MB-435 bearing mice were measured in untreated, optimal 
HK-Luc siRNA and optimal HK-2’OMe-Luc siRNA treatment groups.  No 
differences were detected in the cytokine levels among the different treatment groups. 
 
3.4.6 Nuclease stability of HK/siRNA polyplexes 
The integrity of HK/siRNA polyplex may be sensitive to the serum components in 
vivo (Buyens, Meyer et al. 2010).   PEGylated polymers may augment the stability of 
the polyplex, by reduced binding of serum components.  To investigate their stability 
in mouse serum, HK polyplexes were incubated in the presence of varying amounts 
of serum for one hour at room temperature and then analyzed by gel electrophoresis 
(3% agarose).  As shown in Table 1, increased dissociation of siRNA was observed 
from all carriers as the serum concentration was increased to 50% and above.  Among 
the polyplexes, the unmodified H3K(+H)4b/siRNA polyplexes were less stable than 
the modified HK polyplexes.  There was little difference in the stability in serum 




Table 3.1. Stability of HK/siRNA polyplexes in serum     
[Serum] 
Peptides 
0% 10% 50% 75% 
H3K(+H)4b 89.99% ± 0.77% 87.18% ± 1.39%  64.62% ± 3.38%**  51.46% ± 3.20%** 
(RGD-PEG)H3K(+H)4b/H2K4b 94.93% ± 0.26% 92.89% ± 2.21% 83.58% ± 2.46% 73.32% ± 2.18% 
(RGD-PEG)4H3K(+H)4b/H2K4b 88.09% ± 3.33% 95.12% ± 0.42% 84.09% ± 0.43% 75.41% ± 3.37% 
 
Unmodified H3K(+H)4b and modified H3K(+H)4b/H2K4b carriers in complex with 
siRNA were incubated at various concentrations of mouse serum (0%, 10%, 50% and 
75%) for 1 hr. Gel retardation was then used to measure the stability of the polyplexes 
as described in the Methods section.  Compared to unmodified H3K(+H)4b/siRNA 
polyplexes, the two PEGylated HK polyplexes had greater stability at high serum 
concentration (50%, 75%); **, P < 0.01.  The data represent the mean ± SD of 





To develop more effective carriers of siRNA, we compared two ligand modified HK 
peptides with an unmodified HK peptide.  The two cRGD-PEG HK peptides differed 
in the number and location of cRGD-PEG conjugates on the polymer.  One highly 
modified HK polymer with a cRGD-PEG conjugated to each branch was made that 
we thought would have greater tumor uptake and selectivity.  Nevertheless, we were 
concerned that such a modification on each branch might interfere with binding to 
siRNA.  To investigate this, an HK peptide with only one cRGD-PEG attached to its 
core was prepared and was expected to bind siRNA more effectively because the 
branching arms were not modified.  Surprisingly, neither modified HK polymers by 




together with the inability to determine their particle size by DLS, suggest that a 
stable nanoparticle was not formed.   
 
Nevertheless, combining modified H3K(+H)4b with unmodified H2K4b when mixed 
with siRNA did form stable nanoparticles that could effectively silence their target in 
vivo.  Because H2K4b alone previously was not an effective carrier of siRNA in 
silencing its targets (Leng, Scaria et al. 2005) and reduced amounts of H2K4b were 
used to form the polyplex, it is likely that H2K4b has a supportive role in forming the 
polyplex, but not a primary role in the siRNA polyplex silencing role of the target.  
H2K4b was selected as a helper peptide because of its high content of lysines and its 
greater ability to condense nucleic acids compared to other HK peptides.  It will be 
interesting to test polyplexes using other unmodified HK peptides (i.e., H3K(+H)4b) 
that are significantly more effective as carriers of siRNA, even though they are less 
efficient in condensing nucleic acids compared with H2K4b.  The data in this study 
are consistent with the notion that H2K4b binds tightly with siRNA and provides a 
central nidus to which the modified H3K(+H)4b then binds.  Such a model is similar 
to what the results shown by Kim et al. with their carrier/siRNA complexes.  In that 
model, although the PEGylated siRNA did not effectively silence its cellular target, a 
combination of PEI with the targeted PEGylated siRNA was effective; PEI was 
posited to form the central core and stabilize the siRNA polyplex (Kim, Jeong et al. 
2006; Kim, Jeong et al. 2008).  Although the modified and unmodified HK peptides 




determine whether sequential addition of H2K4b first to the siRNA, followed by the 
modified H3K(+H)4b might increase the efficacy of the carrier.  
         
Moreover, since both cRGD-PEG modifications of H3K(+H)4b did not form an 
effective or a defined siRNA polyplex without the addition of an unmodified HK 
polymer (i.e., H2K4b), it is unclear whether any PEG modifications to the 
H3K(+H)4b polymer will result in a stable siRNA polyplex.  We initially anticipated 
that singly modified H3K(+H)4b would bind more tightly with siRNA and form a 
more stable and defined particle compared to the highly modified H3K(+H)4b.  
Nevertheless, utilizing fluorescent quenching assays we determined that limited and 
highly modified HK peptides had markedly reduced binding with siRNA (data not 
shown).  Limited modification of the branches has been considered but we have not 
determined a synthetic approach for site specific addition of cRGD-PEG to one or 
more branches.  Alternatively, smaller molecular weight PEG conjugated to HK 
peptides than the 3400 MW PEG that we have used in this data may enable HK to 
bind more effectively with siRNA and form stable HK/siRNA polyplexes.  
  
In contrast to most carriers in vivo that were identified from the most promising 
carriers in vitro, we found in this study that the most effective HK carrier in vitro was 
not the optimal carrier in vivo.  Of the HK investigated, unmodified H3K(+H)4b was 
the most effective carrier in vitro, whereas the modified H3K(+H)4b/H2K4b carrier 
of siRNA had no observed silencing activity in cell culture experiments.  In contrast, 




the modified HK polyplexes in vivo and correlated with the number of cRGD-PEG 
per HK.  Increased multivalency based on the ligand conjugated to the drug or 
complex is known to augment internalization (Schraa, Kok et al. 2002; Boturyn, Coll 
et al. 2004) and this provides the likely rationale for greatest activity by the highly 
modified H3K(+H)4b polyplex in vivo.  It is not at all clear why efficient silencing of 
luciferase was observed in vivo but not in vitro with the modified HK polyplexes.  
Although the literature is consistent with my results that PEGylation of the polyplex 
may decrease uptake in vitro and enhance accumulation of the polyplex within the 
tumor tissue, addition of cell-specific ligands such as cRGD to PEG usually augments 
uptake of polyplexes not only in vivo but also in vitro (Hood, Bednarski et al. 2002; 
Schiffelers, Ansari et al. 2004; Kim, Yockman et al. 2005; Kim, Yockman et al. 2006; 
Li and Huang 2006; Li, Chen et al. 2010).  Indeed, previous groups have found that 
cRGD conjugated nanoparticles (with or without PEG) selectively targeted αvβ3 
integrins on the cell surfaces of MDA-MB-435 cells in vitro and in vivo (Arap, 
Pasqualini et al. 1998; Kim, Yockman et al. 2005; Kim, Yockman et al. 2006; 
Yoshimoto, Ogawa et al. 2008; Lee, Lee et al. 2009).  Although modification of 
H3K(+H)4b with cRGD-PEG did not enhance uptake or silencing with siRNA in 
vitro, the in vivo results demonstrating down-regulation of luciferase in tumors 
formed by MDA-MB-435 cells suggest that modification of HK greatly augmented 
silencing activity of the siRNA polyplex.  This is further bolstered by my finding that 
similarly modified HK were effective and specific carriers of luciferase-expressing 
plasmids to MDA-MB-435 tumor xenografts compared to other tissues (data not 




were effective in vitro, there are few other studies (Solodin, Brown et al. 1995; Lee, 
Marshall et al. 1996; Love, Mahon et al. 2010) demonstrating that more efficient 
carriers in vivo were ineffective in vitro.  The importance of this observation is that it 
suggests that until alternative screening methods to evaluate carriers are developed 
for in vivo models, it is likely many other carriers that are particularly effective in 
vivo will never be identified.   
 
Delivery remains the major obstacle to achieving meaningful RNAi silencing. 
Consequently, my primary goal in this study was to develop a more effective carrier 
of siRNA to tumor xenografts.   On the basis of the current results, we anticipate that 
the (RGD-PEG)4H3K(+H)4b/H2K4b combination will be significantly more effective 
carrier than the unmodified carrier for siRNA in targeting oncogenes of tumor 
xenografts.  Furthermore, the silencing of luciferase by the cRGD-targeted 
HK/siRNA polyplex appears to be specific, as evidenced by the minimal silencing by 
the control siRNA and low induction of cytokines by the HK/siRNA polyplex. 
Indeed, αvβ3 integrins are expressed not only by tumor cells but also endothelial cells.  
The conjugation of cRGD peptide as a targeting agent for αvβ3 integrins advances the 
HK polymer selective for both tumor and endothelial cells.  However, it requires 
more effort for the cRGD modified HK polymers to permeate leaky tumor 
vasculatures and specifically silenced the target in tumor xenografts.  Although the 
efficacy of cRGD-PEG targeted HK as a carrier of siRNA targeting tumors and 
angiogenesis requires further validation, the studies thus far have indicated that 





My silencing tumor xenograft model examined whether targeted HK/siRNA 
polyplexes could effectively traversed the endothelial cell barrier to silence Luc 
expressed by tumor cells. Nevertheless, it is likely that the cRGD-HK/siRNA 
polyplexes will also target the more readily accessible αvβ3-expressing endothelial 
cells of tumors. In addition to cyclic RGD peptides, other tumor-selective ligands 
could be conjugated to the HK peptides to target tumor cells and silence their 
oncogenes (Sugahara, Teesalu et al. 2009).  Although the efficacy of cRGD-PEG 
targeted HK as a carrier of siRNA targeting tumors and angiogenesis requires further 
validation, the studies thus far have indicated that modified HK is a promising 






Chapter 4: Surface Modified HK/siRNA Polyplexes with 
Enhanced Pharmacokinetics and Tumor Growth Inhibition  
 
4.1 Abstract 
We characterized in this study the pharmacokinetics and antitumor efficacy of 
histidine-lysine (HK)/siRNA polyplexes modified with PEG and a cyclic RGD 
(cRGD) ligand targeting αvβ3 and αvβ5 integrins.  Using non-invasive imaging, 
systemically administered surface modified HK/siRNA polyplexes exhibit nearly 4-
fold higher blood levels, 40% higher accumulation in tumor tissue, and 60% lower 
luciferase activity than unmodified HK/siRNA polyplexes.  A surface modified 
HK/siRNA polyplex with an siRNA targeting Raf-1 was also found to be more 
effective in reducing MDA-MB-435 tumor growth.  Repeated systemic 
administration of the selected surface modified HK/siRNA polyplexes targeting Raf-1 
showed 35% greater inhibition of tumor growth than unmodified HK/siRNA 
polyplexes and 60% inhibition of tumor growth compared to untreated mice.  Thus, 
improved blood pharmacokinetic results and tumor localization observed with the 
integrin-targeting surface modification of HK/siRNA polyplexes correlated with 
greater tumor growth inhibition.  This investigation reveals that through control of 
targeting ligand surface display in association with a steric PEG layer, modified 
HK/siRNA polyplexes show promise to advance RNAi therapeutics in oncology and 





RNAi silencing of oncogenes via siRNA has a great potential for cancer treatment, 
but its application is limited by several substantial obstacles.  For example, necessary 
advances include avoiding siRNA degradation by nucleases in blood and tissues, 
minimizing side effects of the siRNA or delivery system, transport of the highly 
negative charged siRNA to target tissue and then across cellular membranes, and 
shifting intracellular trafficking away from lysosomal degradation to endosomal lysis.  
After considerable exploration of a wide range of approaches, including chemically 
protective analogues alone, antibody-carrier chimerae and cell-penetrating peptide 
conjugates, most efforts to achieve these milestones are now focused on developing 
target-specific and biologically metastable nanoparticle carriers for siRNA 
oligonucleotides (Song, Zhu et al. 2005; Bartlett and Davis 2008; Peer, Park et al. 
2008; Yang, Dou et al.).   
 
Whereas there have been no FDA-approved siRNA carriers for systemic treatment, a 
few have advanced to clinical trials (clinicaltrials.gov) (Brower 2010; Davis, 
Zuckerman et al. 2010; Alsina, Tabernero et al. 2012; Strumberg, Schultheis et al. 
2012).  These early clinical trials with different carriers encourage testing other pre-
clinical carriers siRNA that have therapeutic efficacy in animal models, including 
synthetic polymers, peptides, siRNA aptamers, neutral and cationic liposomes (see 
review (Leng, Woodle et al. 2009)).  To investigate siRNA-mediated gene silencing 
in tumor cells, Mixson’s lab has synthesized a number of branched histidine-lysine 




protect siRNA via electrostatic interaction, pH-sensitive histidines play an important 
role in buffering the acidic endosomes and may interact with the endosomal 
membrane, aiding the endosomal escape of siRNA.  Many other investigators have 
reported on the use of histidine-containing peptides for DNA plasmid or siRNA 
delivery (Midoux and Monsigny 1999; Putnam, Gentry et al. 2001; Hatefi, Megeed et 
al. 2006; Kichler, Mason et al. 2006).  By varying the amino acid sequence and 
number of branches, a four-branched polymer, H3K(+H)4b, with repeating patterns 
primarily of –HHHK-, was found to be the most effective and least toxic carrier of 
siRNA in vivo (Leng, Scaria et al. 2008).   
 
Although in vitro and in vivo tumor growth inhibition indicative of therapeutic 
efficacy has been achieved with non-ligand targeted HK polyplexes, a more stable 
and targeted delivery system is thought necessary to improve the therapeutic index 
and range of siRNA gene targets.  To improve the stability of the siRNA polyplex, 
surface coatings with hydrophilic polymers such as polyethyleneglycol (PEG) or 
carbohydrates such as hyaluronic acid and oligo-maltose have been studied (Jiang, 
Park et al. 2008; Li and Huang 2008).  Such modifications shield the polyplex surface 
to prevent protein binding, reduce reticuloendothelial uptake, and/or extend the 
circulation time in vivo.  On the other hand, such hydrophilic coated polyplexes can 
also exhibit a decrease in cellular uptake due to steric hindrance of the surface layer.   
 
To circumvent steric hindrance leading to decreased cellular uptake, ligands for 




improved cellular uptakes in a wide array of delivery systems (Kircheis, Wightman et 
al. 2001; Hood, Bednarski et al. 2002; Schiffelers, Ansari et al. 2004; Li and Huang 
2008).   In this chapter, the cRGD-PEG conjugate was attached to the N-terminal 
lysine on each branch of H3K(+H)4b to target selectively αvβ3 and αvβ5 integrins that 




Fig. 4.1. Schematic illustration of (cRGD-PEG) modification patterns and HK/siRNA 
polyplex formation.   
Each of four N-terminal branches was conjugated to a single (cRGD-PEG).  A two-
step mixing was utilized to prepare modified polyplexes: (cRGD-PEG)4H3K(+H)4b 
was first added to a helper peptide, H2K4b.  The resulting mixture was then mixed 
with siRNA at room temperature for 30 min to form HK/siRNA polyplexes.  
 
We previously determined the optimal cyclic RGD and PEGylation patterns on 
H3K(+H)4b (Fig. 3.3) for systemically administered siRNA targeting the luciferase 
gene in a bioluminescence mouse model.  To increase binding with siRNA and form 




predominant repeating groups is –HHK–) was combined with the ligand-PEG 
modified HK peptide (RGD-PEG)4H3K(+H)4b and with siRNA, resulting in 
HK/siRNA polyplexes that provided effective gene silencing without cytokine 
induction in vivo (Chou, Leng et al. 2011).  In the current study, we further 
investigate the cRGD targeted HK/siRNA polyplexes in terms of pharmacokinetics, 
biodistribution and antitumor efficacy and compare them to unmodified HK/siRNA 
polyplexes.  The cRGD-PEG modification of HK/siRNA polyplexes extended the 
half-life in the blood and showed greater tumor accumulation, resulting in reduction 
of luciferase activity by more than 70%.  Consistent with these effects on 
pharmacokinetics and biodistribution, the ligand-targeted HK/siRNA polyplex 
showed enhanced antitumor efficacy with an siRNA targeting the Raf-1 oncogene. It 
reduced Raf-1 mRNA and protein expression and it suppressed growth of MDA-MB-
435 subcutaneous xenograft tumors in mice.  
 
4.3 Materials and Methods 
4.3.1 Animals 
Female athymic mice (4 to 8 weeks old, body weight ~20 g) were purchased from 
NCI Frederick.  All experiments were performed in accordance with the regulations 
of the Institutional Animal Care and Use Committee of the University of Maryland 





4.3.2 Cell line 
A human malignant cell line MDA-MB-435, stably expressing Firefly luciferase 
(stable transformation by electroporation with the linearized pCpG-Luc plasmid), was 
cultured and maintained in Dulbecco’s minimal essential medium (DMEM) 
containing 10% fetal calf serum (FCS) and 20 mM glutamine. The pCpG-Luc 
plasmid was made by ligating the luciferase gene (digested from pMOD-Luc plasmid, 
InvivoGen, San Diego, CA) into the multiple cloning site of pCpG-mcs (InvivoGen).  
This cell line is identical to the cell line involved in chapter 2 and 3. 
 
4.3.3 Synthesis, sequences, and chemical modification of HK peptides 
Branched peptides, H2K4b and H3K(+H)4b with predominant repeating groups, –
HHK– and –HHHK–, respectively were synthesized on a Rainin Voyager synthesizer 
(PTI, Tucson, AZ) by the biopolymer core facility at the University of Maryland, as 
previously described (Leng and Mixson 2005).  Each of four terminal branches 
emanates from the 3-lysine core: for H3K(+H)4b, the branch sequence is 
KHHHKHHHKHHHHKHHHK;  for H2K4b, the branch sequence is 
KHKHHKHHKHHKHHKH-HKHK.  For modified H3K(+H)4b, cyclic (c)RGD and 
PEG (3.4 kD) were conjugated to each N-terminal branch as described in 3.3.3, 
resulting in four (cRGD-PEG) conjugates per HK peptide, (RGD-PEG)4H3K(+H)4b 






Sequences of siRNA targeting luciferase (siLuc) were as follows: sense, 5’-CUG-
CAC-AAG-GCC-AUG-AAG-A-dTdT-3’; antisense, 5’-UCU-UCA-UGG-CCU-
UGU-GCA-G-dTdT-3’, targeting 5’-CTG-CAC-AAG-GCC-ATG-AAG-A-3’. siLuc 
was also used as the control siRNA for studying inhibition of tumor growth.  Raf-1 
siRNA duplex (siRaf-1) was as follows: sense, 5’-GCA-UCA-GAU-GAU-GGC-
AAA-C-dTdT-3’; antisense, 5’-GUU-UGC-CAU-CAU-CUG-AUG-CdTdT-3’, 
targeting 5’-GCA-TCA-GAT-GAT-GGC-AAA- C-3’ (Dharmacon, Lafayette, CO).  
Luciferase siRNA was conjugated to Alexa Fluor 546 (Dharmacon) or a near infrared 
dye, Cy5.5 (Sigma-Aldrich, St. Louis, MO), on the 5’ end of the sense strand.  Each 
siRNA was maintained in siRNA buffer (Dharmacon) for 30 min at RT for annealing 
the duplex. 
 
4.3.5 Preparation and biophysical properties of HK polyplexes 
The ternary (RGD-PEG)4H3K(+H)4b/H2K4b/siRNA and H3K(+H)4b polyplexes 
were prepared as described in chapter 3 for experiments in vivo .  As defined by gel 
retardation assays and the biophysical characteristics, the optimal N/P ratios for 
H3K(+H)4b/siRNA and (RGD-PEG)4H3K(+H)4b/ H2K4b/siRNA were about 2.2/1 
(w/w) (N/P ratio, 4/1) and 4.0/0.8/1 (w/w/w; N/N/P ratio 3/1/1) used in this study.  
   
For these ratios of HK/siRNA polyplexes, the size and zeta potential were determined 
with the Zetasizer (Malvern, Westborough, MA) prior to their injection. The size is 




scattering of the particles at a 90° angle carried out with software provided by the 
instrument manufacturer.  Each particle size and zeta potential data point represents 
the mean ± S.D. of four measurements on separate preparation. 
 
4.3.6 Fluorescence quenching assay 
The relative binding affinity between various HK polymers and siRNA was studied 
with Alexa 546-labeled siRNA (λex = 550 nm, λem = 570 nm, Dharmacon, Lafayette, 
CO).  Fluorescent-labeled siRNA (0.14 µM, 100 µl) in phosphate buffer (10 mM, pH 
7) was added to a 96-well plate, and changes in fluorescence were then measured by 
adding 0.033 µM increments of H3K(+H)4b, H2K4b, (RGD-PEG)4H3K(+H)4b, or 
(RGD-PEG)4H3K(+H)4b/H2K4b.  After incubation of HK and siRNA at room 
temperature for 20 min, the fluorescence intensity was measured by a Wallac Victor 3 
1420 multilabel counter (Perkin Elmer, Boston, MA), and the relative fluorescence 
intensity was normalized after subtracting background levels.   
 
4.3.7 Preparation of HK/siRNA polyplexes for treatment of tumor xenografts 
HK/siRNA polyplexes were prepared as previously described (Chou, Leng et al. 
2011).  Briefly, for unmodified polyplexes, H3K(+H)4b peptide (88 µg in 150 µl of 
water) was rapidly added to the siRNA (40 µg in 150 µl water) and mixed with a 
Vortex mixer.   For the modified HK combination, the (RGD-PEG)4H3K(+H)4b 
peptide (160 µg in 150 µl of water) or PEG4H3K(+H)4b (152 µg in 150 µl of water) 




min at room temperature before siRNA was added.  The polyplexes were allowed to 
form for 40 min at room temperature following by injection and biophysical 
characterization.   
 
4.3.8 Biodistribution, pharmacokinetics, and bioluminescence  
MDA-MB-435 cells (2 x 106 cells) expressing luciferase were injected into the mid-
clavicular line of female nude mice (NCI Frederick).  After tumors grew to about 180 
mm3, mice were separated into three siRNA treatment groups: aqueous siLuc, 
H3K(+H)4b/siLuc (w/w, 2.2/1), and (RGD-PEG)4H3K(+H)4b/H2K4b/siLuc (w/w/w, 
4/0.8/1).  The aqueous siRNA or HK/siRNA polyplexes containing 40 µg of siLuc 
(including 5% (2 µg) of Cy5.5-labeled siLuc) were administered in the tail vein.  For 
biodistribution studies, the mice were imaged by the IVIS-200 optical imaging system 
(Xenogen Corp., Alameda, CA) at 0, 15, 30, and 60 min, and 2, 4, 6, and 24 h post-
injection.  Fluorescence emission at the tumor location, given as relative units after 
normalization of maximal and minimal intensities (Lee, Veiseh et al. 2010), was 
measured with regions of interest of equal size at specified time points.  
Biodistribution imaging and tumor luciferase activity were measured by IVIS-200 
before and 48 h after siRNA treatment targeting luciferase (Chou, Leng et al. 2011).  
       
Similarly, to determine the effects of PEG and cRGD modifications, the 
PEG4H3K(+H)4b/H2K4b/siLuc polyplexes (w/w/w, 3.8/0.8/1) were compared with 




silence luciferase in tumor xenografts of about 60 mm3.  Tumor imaging with IVIS-
200 imaging was done 48 h after injection of the polyplexes. 
 
For pharmacokinetic experiments, tumor-bearing mice were treated with Cy5.5-
labeled Luc siRNA (5% of total Luc siRNA) in complex with different formulations 
of HK peptides as described above for the biodistribution study.  At several time 
points ( 2, 5, 10, 15, 25, 45, 60, and 120 min),  blood (100 µl) was collected and 
serum was isolated (Li, Chen et al. 2008).   The serum (30 µl) was then mixed with 
PBS (20 µl) in a 96-well clear bottom plate, and the fluorescence signal was imaged 
by the IVIS-200 system.  The concentration of the polyplexes were calculated from a 
standard curve of fresh aqueous siRNA or polyplexes (Lee, Veiseh et al. 2010).  As 
described previously (Merkel, Librizzi et al. 2009; Rowland and Tozer 2011), the 
pharmacokinetic analysis of the data was performed using a two-compartment model  
(f = A*exp(-αt) + B*exp(-βt)) with first order adsorption and elimination from the 
central compartment by using Sigma Plot, 11.0.  After curve fitting of the data, the 
PK parameters were calculated based on the following expressions: 
Terminal half-life:  ln 2 𝛽 
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4.3.9 Inhibition of tumor growth and Raf-1 expression 
Mice with MDA-MB-435 xenografts (about 25 mm3 in size) were separated into four 
treatment groups: untreated, H3K(+H)4b/Control siLuc, H3K(+H)4b/siRaf-1, and 
(RGD-PEG)4H3K(+H)4b/H2K4b/siRaf-1.  HK/siRNA polyplexes with same w/w 
ratios as described above were injected intravenously three times a week for a total of 
6 or 7 treatments depending on the experiment.  Tumor volume was determined 
before each treatment with skin calipers by using the formula 1/ 2 × length × width2.  
Two days after the last injection, the mice were euthanized and total RNA was 
isolated from excised tumor xenografts using the RNeasy mini kit (Qiagen, Hilden, 
Germany).  Expression of Raf-1 (368 nt) and β-actin (294 nt) mRNA was assessed by 
reverse transcriptase-polymerase chain reaction (RT-PCR) as described previously 
(Leng and Mixson 2005).  RT-PCR products were then loaded onto a 3% agarose and 
subjected to electrophoresis at a constant voltage of 100 V for 90 minutes in TBE 
buffer containing ethidium bromide.  The band density was visualized on a UV 
transilluminator with a wavelength of 365 nm and the image was digitized and 
analyzed by UN-SCAN-IT (Silk Scientific, Orem, UT).   
 
4.3.10 Immunohistochemical detection of Raf-1 and Ki67, and analysis of 
apoptosis using the TUNEL assay 
Tumors were fixed in 10% formalin for 24 h and processed as paraffin-embedded 
tissue sections.  Immunostaining was performed according to the manufacturer's 
protocol (Vector, Versatile ABC, Burlingame, CA).  Briefly, tumor sections were 




by maintaining tissue in 10 mM citrate buffer, pH 6.0, at boiling point for 40 min.  
Endogenous peroxidase and non-specific binding were blocked by 3% H2O2 for 10 
min and 5% goat serum for 30 min, respectively.  For detection of Raf-1 and Ki67, 
tissue sections were incubated with rabbit anti-human polyclonal antibody (Raf-1: 
1:50 dilution, Ab-259, Genscript, Piscataway, NJ, USA; Ki67: 1:50 dilution, 
Chemicon, Ramona, CA, USA) at 4 °C overnight and secondary horseradish 
peroxidase-labeled antibody was added for 30 min. The chromogen diaminobenzidine 
(DAB) was applied for 5 min to permit color development.  Finally tissue was 
dehydrated and mounted with glass coverslips.  Four arbitrarily picked brightfield 
images were converted to normalized blue images (Brey, Lalani et al. 2003) allowing 
automatic classification (quantification) of  positive DAB staining.  The TUNEL 
assay was performed on paraffin-embedded tissue according to the manufacturer’s 
instruction (FragEL DNA Fragmentation Detection Kit, Calbiochem, San Diego, 
CA).  The tissue sections were incubated with terminal deoxynucleotidyl transferase 
for 90 min after specimen permeabilization and endogenous peroxidase inactivation. 
The labeling reaction was then terminated and tumor sections were stained with DAB 
substrate. 








aThe size and zeta potential of polyplexes were measured before their systemic 
administration to mice.  bEach data point represents the mean ± S.D. of four 
measurements. 
Peptide Size (nm)a Zeta potential (mV)a 
H3K(+H)4b 166.7 ± 24.8b 41.5 ± 5.5 
PEG-HK 68.6 ± 11.3 17.3 ± 1.3 






4.4.1 Polyplexes formed with the combination of modified and unmodified HK 
peptides 
Relative binding affinities of HK peptides to siRNA were determined by titration of 
Alexa 546-labeled siRNA with different peptides.  When the peptide binds siRNA, 
fluorescence intensity is attenuated due to polyplex formation.  These results of these 
quenching studies corroborated a previous study that used a gel retardation assay 
(Chou, Leng et al. 2011), confirming that a combination of unmodified H2K4b and 
(RGD-PEG)4H3K(+H)4b was required to form the ternary polyplexes (Figs. 4.1 and 
4.2).  The unmodified HK peptides, H2K4b and H3K(+H)4b, had high affinity for 
siRNA to form polyplexes (as evidenced by decreased fluorescence at N/P ~ 1), the 
modified (RGD-PEG)4H3K(+H)4b peptide alone showed negligible binding to 
siRNA.  A combination of unmodified H2K4b peptide, with a greater charge density, 
and the RGD-PEG modified H3K(+H)4b peptide showed quenching of the siRNA 
that was intermediate between the modified alone and unmodified peptides, 
suggesting that both peptides are present in the polyplex (Fig. 4.2).  The size and zeta 
potential  of the unmodified or combined (RGD-PEG)4H3K(+H)4b/H2K4b/siRNA 
polyplexes used for in vivo experiments are shown in Table 4.1.  To simplify the 
nomenclature, the combination of (RGD-PEG)4H3K(+H)4b and H2K4b will be 





4.4.2 Enhanced pharmacokinetics with modified HK/siRNA polyplexes 
The concentration of polyplexes in blood was determined by measuring near infrared 
(NIR) fluorescence from Cy5.5-labeled siRNA, alone or incorporated within the 
polyplexes (Fig. 4.3).  The advantage of the near infrared based methodology is its 
high sensitivity and low background, thereby requiring only small amounts of blood 
to detect the Cy5.5 signal.  At indicated time points up to 2 hours, blood was drawn 
and the amount of siRNA in the serum was measured.  Fifteen minutes after injection, 
the concentrations of the siRNA, alone or as polyplexes, decreased to less than 10% 
of the injected dose.  As shown in figure 4.3, aqueous siRNA and unmodified 
HK/siRNA polyplexes were eliminated substantially faster than the modified RP-
HK/siRNA polyplexes.  The key pharmacokinetic parameters were determined by 
fitting the data with a bi-compartment model (Table 4.2) (Rowland and Tozer 2011) 
and the results of curve fitting were shown in figures 4.4-4.6 and table 4.3.  The 
sterically stabilized and ligand-targeting polyplexes had a 3-fold greater terminal half-
life (t1/2b) and mean residence time (MRT), and a 4-fold increase in the area under the 
curve compared to unmodified HK polyplexes.  In addition, the surface modification 
of the polyplexes markedly reduced elimination clearance (CL) by 10-fold.  Thus, all 
pharmacokinetic parameters indicated that surface modification of the HK/siRNA 
polyplexes greatly increased its residence time in the bloodstream which suggests that 







Fig. 4.2. Relative binding affinity of HK peptide formulations with siRNA.   
Relative binding affinity of four HK peptide formulations (H3K(+H)4b; H2K4b; 
(RGD-PEG)4H3K(+H)4b; (RGD-PEG)4H3K(+H)4b/H2K4b (RP-HK)) for Alexa 
546-labeled siRNA was studied in 10 mM phosphate buffer, pH 7.0.  Relative 
fluorescence intensity is the percentage of unbound siRNA after subtraction of 
background fluorescence.  See Results section for further details. 
  
4.4.3 Increased localization of cRGD-PEG modified HK/siRNA polyplexes 
The tumor-specific targeting efficacy was assessed by NIR fluorescence imaging of 
Cy5.5-conjugated siRNA with a non-invasive imaging system, IVIS-200, before and 
at specified times after injection (Fig. 4.7A).  Autofluorescence was observed in the 
abdomen, but this did not interfere with measurement of the polyplex levels within 
tumors.  As soon as 15 min after injection, the modified RP-HK/siRNA polyplexes 
gave higher fluorescence in tumor tissue than that of the unmodified HK/siRNA 
polyplexes.  In contrast, administration of aqueous siRNA resulted in minimal tumor 
fluorescence, indicative of negligible siRNA uptake.  The amount of targeted RP-




fluorescence (Fig. 4.7B).  While unmodified HK/siRNA polyplexes rapidly reached 
maximal accumulation within the tumor 30 min after injection, the modified RP-
HK/siRNA polyplexes required 60 to 120 min after injection to achieve maximal 
levels.  Compared to accumulation of unmodified HK polyplexes within tumors, 
accumulation of modified RP-HK polyplexes was 40% higher (P < 0.01) at 60 min.  
Although the polyplex distribution in the major organs was difficult to assess due to 
autofluorescence in the abdominal region, significant accumulation of fluorescence 
with the aqueous siRNA-treated group occurred earlier in the spleen compared to the 
HK/siRNA polyplex groups.  Not surprisingly, fluorescence in aqueous siRNA-
treated mice was observed in the bladder with the first image (15 min), whereas 
siRNA of the polyplexes was not detected at a significant level in the bladder until 2 h 
after injection.   There was little difference in organ fluorescence accumulation 
between the modified RP- and unmodified HK polyplexes except that accumulation 







Fig. 4.3. Serum pharmacokinetics of Cy5.5 labeled siRNA and polyplexes.   
A semilogarithmic plot of serum concentration vs. time for up to 2 h after intravenous 
injection of siRNA alone or in complex with the unmodified HK or modified RP-HK 
peptides. The data represent the mean ± SD of %ID/ml (n = 4 per carrier) where % 
ID/ml is the percentage of injected dose per milliliter of serum. 
 










Aqueous siRNA 27.7 18.50 126.3 ± 52.7 41.4 
H3K(+H)4b: siRNA 86.6 16.62   98.0 ± 58.6 129.5 
RP-HK: siRNA 256.7 1.57 385.0 ± 92.4 374.7 
 
at1/2β, terminal half-life; bCL, clearance; cAUC2h, area under curve from 0 to 2 h; 





Curve fitting results of aqueous siRNA or polyplex concentration in the serum using 
two-compartment model: 
 
Fig. 4.4. Curve fitting of the concentration of aqueous siRNA in serum  







Fig. 4.5. Curve fitting of the concentration of unmodified polyplexes in serum  






Fig. 4.6. Curve fitting of the concentration of modified polyplex in serum  
R2 > 0.99 
 
Table 4.3. The coefficients of two-compartment model derived from curve fitting. 
 
A B α β 
Aqueous siRNA 0.2542 0.0587 0.718 0.025 
H3K4b 0.3631 0.0111 0.224 0.008 
RP-HK 0.3208 0.082 0.2326 0.0027 
 






Fig. 4.8. Real-time biodistribution of Cy5.5 labeled siRNA and polyplexes.  
(A) Representative biodistribution of Cy5.5-labeled siRNA in a mouse, with the 
siRNA administered as an aqueous solution, unmodified HK polyplex or RP-HK 
polyplex.  Times 15, 30, 60, 120 min, and 4, 6, and 24 h are shown. Red circles 
encircle the tumors (B) Fluorescence emission localized at the tumor was measured 
for the different siRNA groups. The data represent the mean ± SD of fluorescence of 
four determinations for each carrier. **, P < 0.01; RP-HK carrier vs. unmodified HK 




4.4.4 The correlation between tumor luciferase silencing and pharmacokinetics 
The correlation between PK/biodistribution and target gene silencing of the different 
polyplexes was determined with same group of mice, which had tumors expressing 
luciferase.  Luciferase activity was measured by the IVIS imaging system before and 
48 h after treatment (Fig. 4.8).  Compared to aqueous siLuc, the modified RP-HK 
siLuc polyplexes inhibited luciferase expression by about 70%, whereas the 
unmodified HK siLuc polyplexes only inhibited luciferase activity by about 10%.  
These results with the labeled siRNA were consistent with my previous results with 
unlabeled siRNA (Chou, Leng et al. 2011).  Thus, the labeled siRNA apparently does 
not interfere with the functional characteristics or activity of the HK polyplexes in 
silencing its target.  Consequently, down-regulation of luciferase activity correlated 
with increased blood circulation time and tumor tissue accumulation of polyplexes. 







Fig. 4.8. Bioluminescence assay for silencing of luciferase expression.   
The representative mice were from the same treatment groups used for the 
biodistribution study. Panel A and B show tumor bioluminescence images of 
representative mice taken before and 48 h after treatment, respectively. The treatment 
groups in A and B were as follows (from the left to right): aqueous siRNA, 
H3K(+H)4b, and RP-HK polyplexes respectively. (C) The percent silencing of 
luciferase activity by different treatment groups compared to the untreated control 
group represents the mean ± SD of fluorescence of four determinations.  ***, P < 
0.001. 
 
We were particularly interested in determining the contribution of the cRGD targeting 
ligand to the tumor-tissue gene silencing by RP-HK polyplexes.  Consequently, the 
ability of RP-HK polyplexes to reduce the luciferase activity of the tumor was 
compared to HK polyplexes with the same PEGylation but with the cRGD absent 
(Fig. 4.9).  The PEGylated alone HK (PEG-HK) polyplexes silenced luciferase 
activity within tumor xenografts more effectively than unmodified HK but less 
effectively than RP-HK polyplexes.  Moreover, the PEG and cRGD appeared to have 
approximate additive contributions.  The PEG-HK siLuc polyplexes were 60% more 
effective than the unmodified HK siLuc polyplexes (P < 0.05) whereas the RP-HK 
siLuc polyplexes were 50% more effective than PEG-HK siLuc polyplexes (P < 






Fig. 4.9. PEG and cRGD modifications of HK enhance gene silencing in tumor 
xenografts.   
Luciferase siRNA polyplexes with unmodified, PEG or cRGD-PEG (RP) modified 
H3K(+H)4b were systemically administered to tumor xenografts bearing mice.  
Before and 48 h after treatment, luciferase activity was determined by an IVIS 200 
system. The data represent the mean ± SD of luciferase of four determinations for 
each carrier. *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
 
4.4.5 Inhibition of tumor tissue gene expression and growth by targeting Raf-1 
In addition to silencing the luciferase marker, we evaluated the ability of different 
carriers to deliver siRNA targeting the Raf-1 oncogene in vivo.  We examined 
inhibition of MDA-MB-435 tumor growth by modified or unmodified HK/siRNA 
polyplexes with siRaf-1.  Six systemic injections were given via tail vein, three times 
a week for 2 weeks.  As early as the second injection, the modified RP-HK siRaf-1 
polyplexes showed 30% greater reduction in tumor size compared to the untreated 
mice (P < 0.01) (Fig. 4.10A).  In contrast, there was no statistical difference in tumor 




untreated groups.  After the last injection, the modified RP-HK polyplexes reduced 
tumor size 33% more effectively than the unmodified HK polyplexes (P < 0.01) and 
nearly 60% more than tumors of untreated mice (P < 0.01).  Tumor volumes of mice 
treated with the modified RP-HK carrier in complex with a negative control siLuc 
were similar to those of untreated mice. 
 
To evaluate whether reduction in tumor growth rate was dependent on reduction in 
the expression of the Raf-1 oncogene, we determined the Raf-1 mRNA in the various 
treatment groups by RT-PCR.  Compared to the untreated group (Fig. 4.10B), the 
modified HK polyplexes down-regulated Raf-1 mRNA expression by 90% (lane 3), 
whereas the unmodified treatment group decreased the RNA by 60% (lane 2).  The 
correlation between Raf-1 mRNA expression and luciferase activity clearly indicated 
that the target gene silencing was significantly enhanced by ligand-targeting 







Fig. 4.10. MDA-MB-435 tumor growth and Raf-1 mRNA inhibition.   
(A) MDA-MB-435 tumor-bearing mice were separated into four groups when tumor 
size was about 25 mm3: untreated, H3K(+H)4b/siLuc control, H3K(+H)4b/Raf-1 
siRNA, and RP-HK/Raf-1 siRNA.  Treatment was given three times a week for two 
weeks (arrows). Data for each time point represent the mean ± SD of tumor volume 
of five determinations for each treatment group. **, P < 0.01. (B) Raf-1 and β-actin 
mRNA expression was determined by RT-PCR analysis of RNA isolated from tumor 
tissue at day 22. Lanes 1, 2, and 3 represent untreated, unmodified, and modified 
polyplexes treatment group, respectively. 
 
4.4.6 Immunohistological analysis of treated tumor tissue 
Down-regulation of Raf-1 and its downstream effects in tumor tissue of mice treated 
systemically with HK siRaf-1 polyplexes was evaluated by immunohistochemistry.  
Tumors from treated mice were sectioned and stained for Raf-1 and Ki67 as well as 
for apoptosis (with the TUNEL assay) (Fig. 4.11A).  Non-necrotic areas of tumor 




cells were identified (by brown staining) and quantified by analysis of four arbitrarily 
selected normalized blue images (Brey, Lalani et al. 2003).  In viable areas of tumors, 
Raf-1 protein was down-regulated by nearly 40% and 80% in the unmodified and 
modified HK siRaf-1 polyplex treatment groups, respectively, compared to untreated 
groups (Fig. 4.11; P < 0.01, modified vs. unmodified or untreated).  Notably, 
reduction of Raf-1 protein with immunostaining was consistent with Raf-1 mRNA 
suppression determined by RT-PCR.  Furthermore, as evidenced by the cell 
proliferation marker Ki67 (Fig. 4.11), the modified polyplex treatment reduced cell 
proliferation more effectively (50%) than did unmodified treatment or untreated (P < 
0.01, modified vs. unmodified, untreated).  
 
The TUNEL assay was used to assess cellular areas of apoptosis (Fig. 4.11).  
Quantification of staining was not appropriate with TUNEL assay since apoptosis 
region was sporadically distributed (Fig. 4.11B).  Qualitatively, modified RP-HK 
siRaf-1 polyplexes generally induced larger areas of apoptosis than unmodified HK 
siRaf-1 polyplexes.  In conclusion, immunohistological analysis showed greater 
reduction of Raf-1 protein and cellular proliferation as well as increased apoptosis 






Fig. 4.11. Histochemical analysis of Raf-1, Ki67, and apoptosis.  
(A) Scale bars equal 10 µm. (B) Quantification of cells staining positive for Raf-1 and 
Ki67 with different treatments is shown, expressed as the percentage of untreated 
control.  The data represent the mean ± SD of percentage of four images for each 






The potential of RNAi to provide a substantial advance in therapeutics, especially for 
cancer treatment, has been limited due to lack of an efficient carrier.  Mixson’s group 
has methodically investigated improvements in a family of branched histidine-lysine 
peptides carriers of siRNA by altering their sequence and number of branches (Leng, 
Scaria et al. 2008).  While the H3K(+H)4b peptide was demonstrated to be an 
effective carrier of siRNA both in vitro and in vivo, modification of H3K(+H)4b with 
a cRGD targeting ligand, in concert with PEGylation, was found to provide a more 
effective carrier, using an in vivo bioluminescence assay (Chou, Leng et al. 2011).  
Although PEGylation and addition of a tumor-specific ligand were expected to 
increase accumulation of the polyplexes within the tumor, the mechanisms for the 
improved carrier were never investigated nor whether the tumor targeting activity of 
the RP-HK/siRNA polyplexes could translate into greater tumor reduction.  We 
established in this study that the half-life in the bloodstream correlates with increased 
accumulation of the modified HK polyplexes within the tumor.  The improved 
pharmacokinetics of the modified HK polyplexes resulted in significantly greater 
reduction of targeted oncogene expression with a marked decrease in tumor size.    
 
PEGylation can provide tumor targeting by facilitating the enhanced permeability and 
retention (EPR) effect due to an increased blood circulation half-life (Tanaka, 
Shiramoto et al. 2004).  We show here that PEGylation alone of HK/siRNA 




luciferase was further enhanced using targeted RP-HK/siRNA polyplexes (Fig. 4.9).  
Thus, it appears that the cRGD and PEG modifications have important and additive 
contributions.  PEG has been used in numerous studies to increase the hydrophilicity 
of polyparticles including polyplexes, minimize clearance by phagocytic cells, and 
increase the half-life of the polyparticle in vivo (Brannon-Peppas and Blanchette 
2004).  The improved tumor tissue siRNA activity by the PEGylated-only HK/siRNA 
polyplexes was likely the result of surface steric stabilization by PEG, which reduced 
the zeta potential due to an increase in hydrodynamic radius (Woodle, Collins et al. 
1992).  The reduction in zeta potential (Table 4.1) by nearly 50% for RP-HK/siRNA 
polyplexes (23 mV) compared to unmodified HK/siRNA polyplexes (41 mV) is 
attributable to PEG, since the zwitterionic cRGD peptide is not known to alter the 
hydrodynamic surface properties.  Reduction of the surface charge with sterically 
stabilized polyplexes would be expected to inhibit their non-specific attachment and 
internalization by cells, prolong their half-life in the circulation, and importantly 
enhance their ligand receptor-mediated cellular uptake (Levchenko, Rammohan et al. 
2002; Bartlett, Su et al. 2007).  Without steric stabilization, non-selective attachment 
to cell surfaces by highly positively charged unmodified HK/siRNA polyplexes may 
contribute to a larger fractional α clearance and thus slightly lower blood levels 
(AUC) than that of aqueous siRNA.   
 
It may be possible to increase blood circulation and EPR tumor targeting of 
HK/siRNA polyplexes further by conjugation with even higher molecular weight 




weight of PEG as well as the degree of PEGylation significantly influenced the 
circulation time of polylysine/siRNA polyplexes.  By increasing the weight ratio of 
PEG (to polylysine) from 70% to 90%, the circulatory half-life of polyplexes in the 
bloodstream was enhanced by 100-fold (Sato, Choi et al. 2007).  Consequently, 
increasing or modifying the PEGylation of HK/siRNA polyplexes might further 
improve the pharmacokinetic properties and therapeutic window by this mechanism.  
 
An important contribution to tumor tissue targeting appears to be provided by the 
cyclic RGD peptide ligand, attributable to selective binding to the αvβ3 and αvβ5 
integrins that are over-expressed and activated on cell surfaces of both MDA-MB-435 
cancer cells and tumor tissue neovasculature (Wong, Mueller et al. 1998; Hood, 
Bednarski et al. 2002).  The NIR optical fluorescence biodistribution studies on RP-
HK:siRNA demonstrated that ligand-targeted polyplexes accumulated at higher levels 
in the tumor tissue than unmodified polyplexes (Fig. 4.9).  With combined cRGD 
ligand and PEGylation, the RP-HK/siRNA polyplexes gave the greatest improvement 
in pharmacology, biodistribution and tumor tissue targeting siRNA activity, both for a 
constitutively expressed reporter gene and a therapeutic gene, Raf-1.  Perhaps 
surprisingly, the modified RP-HK/siRNA polyplexes resulted in an improved 
pharmacokinetic profile distinct from that observed with a transferrin targeted 
cyclodextrin-based siRNA polyplexes.  In those studies, the blood circulation half-life 
of aqueous siRNA and targeted cyclodextrin/siRNA polyplexes were similar 
(Zuckerman, Choi et al.).  Moreover, accumulation of the targeted 




administration, whereas targeted RP-HK/siRNA polyplexes showed a substantial 
delay: fluorescent siRNA was not observed in the bladder until 2 hours after 
administration.  It is unclear why this difference in renal clearance between the two 
polyplexes occurred, since the particle size of the targeted RP-HK/siRNA polyplexes 
should enable their passing readily through the endothelial fenestrations of the 
glomerulus.  Although several studies, including my results with unmodified 
HK/siRNA polyplexes, have demonstrated a rapid decrease in blood levels of 
polymeric polyplexes within 20 minutes of intravenous administration (Bartlett, Su et 
al. 2007; Merkel, Librizzi et al. 2009), the targeted RP-HK/siRNA polyplexes were 
detected in the blood for up to 2 hours.  The prolong b-phase by which serum levels 
of RP-HK polyplex nearly levels off between 20 minutes and two hours is somewhat 
surprising and may in part represent polyplex absorption to serum proteins.  To date, 
no reported studies of PEGylated polyplexes have achieved the prolonged blood 
circulation observed with PEGylated liposomes (Woodle and Lasic 1992), such as 
wrapsomes (Yagi, Manabe et al. 2009) in which PEG extended the blood half-life in 
mice up to 17 hr.    
 
Inhibition of the target gene was consistent with pharmacokinetics and distribution in 
that luciferase expression was markedly down-regulated by the modified polyplexes.   
Nevertheless, it was still surprising that a single treatment would give rise to over 
70% of gene silencing of luciferase, particularly since many cells expressing 
luciferase are several layers removed from the vasculature.  We corroborated this 




measurement of the luciferase activity from extracts of tumor xenografts.  This 
silencing effect by RP-HK/siRNA polyplexes was nearly identical over a wide range 
of tumor sizes (50 to 180 mm3) (Fig. 4.8) (Chou, Leng et al. 2011), indicating that 
targeting mechanisms such as EPR remained similar (Heneweer, Holland et al.).  
Moreover, the decrease in luciferase activity was homogeneous throughout the tumor, 
further validating the results.  Perhaps more importantly, the reduction of Raf-1 
mRNA and protein expression by 90% and 80%, respectively, further confirms the 
results of luciferase activity.  Several other investigators have also found that non-
viral carriers of siRNA have unexpectedly high rates of silencing their targets 
(Takeshita, Minakuchi et al. 2005; Bartlett and Davis 2006; Ofek, Fischer et al. 2010; 
Yang, Dou et al. 2011).  Taken together, these results strongly suggest that the siRNA 
can selectively silence their targets in the tumor xenograft very efficiently, but the 
mechanisms for this high efficiency remain to be elucidated.   
 
This high efficiency of siRNA delivery to subcutaneous xenograft tumors, observed 
with the RP-HK/siRNA polyplexes, is in marked contrast to other stabilized and 
targeted nucleic acid delivery systems.  It has been suggested that effective siRNA 
delivery to tumor xenografts may be aided by membranous exosomal vesicles, which 
are derived from multivesicular bodies (MVB) and subsequently released from the 
cell (Mears, Craven et al. 2004; Meckes, Shair et al. 2010).  The 40 to 100 nm 
exosomes, which contain specific proteins and RNA including RNA-induced 
silencing complex (RISC), P body component GW182, mRNA, and microRNA, have 




tumor cells (Valadi, Ekstrom et al. 2007; Lakhal and Wood).  Importantly, the 
exosomal mRNA retains its function after transfer to the recipient cell.   Although 
there is yet no evidence that siRNA entrapped within exosomes can shuttle 
intercellularly to target mRNA, exosome-mediated gene transfer has been exploited 
for targeted siRNA delivery across the bloodbrain barrier resulting in 60% gene 
inhibition (Alvarez-Erviti, Seow et al. 2011).  Thus, exosome-mediated intercellular 
communication within tumor cells may have a role in efficient luciferase or Raf-1 
knockdown within the tumor.   Despite the possibility of a biologically mediated 
mechanism having a role in the knock-down of the targeted gene, the importance of 
increasing transfection efficiency of polyplexes and the underpinning mechanisms 
that increase this efficiency should not be minimized.   
 
Although tumor growth was inhibited more effectively with the modified HK 
polyplexes, reduction in tumor size was not equivalent to Raf-1 gene inhibition; that 
is, we did not observe a 90% reduction in tumor size corresponding to the 90% 
knockdown we observed with the Raf-1 gene.  Because tumor proliferation and 
apoptosis are mediated by multiple and complex signal transduction pathways 
regardless of the oncogene targeted, there may be cross-talk and compensatory 
responses between pathways that facilitate the development of resistance to 
therapeutics.  For example, Hoeflich and colleagues have indicated that diminished 
mitogen-activated protein kinase (MEK), downstream of Raf-1, activates PI3K 
pathway driving tumor development in basal-cell like breast cancers (Hoeflich, 




responses, oncogenes such as survivin can be targeted, which may result in greater 
tumor inhibition; for example, siRNA targeting survivin decreased MDA-MB-435 
cellular growth significantly more than targeting Raf-1 (data not shown).   Regardless 
of the oncogene targeted, it will be important to block additional signal pathways to 
suppress tumor growth more effectively.  Moreover, there have been a number of 
studies showing that blocking multiple pathways in malignant tumor cells gives a 
synergistic reduction in tumor size (Spankuch, Kurunci-Csacsko et al. 2007; Sun, Du 
et al. 2011; Xiong and Lavasanifar 2011).  Consequently, future work in Mixson’s 
laboratory will focus on enhancing siRNA delivery systems in combination with 
synergistic inhibitory therapies that target interactive signal pathways. 
 
4.6 Conclusion 
We investigated the pharmacokinetics, biodistribution, and therapeutic activity of RP-
HK/siRNA polyplexes targeting Raf-1 gene expression in a subcutaneous xenograft 
tumor model in mice.  Consistent with greater silencing of the reporter gene in tumor 
xenografts, the pharmacokinetics showed that RP-HK/siRNA polyplexes have an 
increased half-life in the bloodstream and greater accumulation of siRNA within the 
tumor.  Consequently, translational studies were undertaken with a therapeutic siRNA 
candidate targeting Raf-1.  The results show that targeted HK/siRNA polyplexes gave 
a significantly greater reduction of the targeted tumor tissue gene expression, at both 




with histochemistry measurements of downstream effects supporting an siRNA-








Chapter 5:  Conclusion and future work 
 
5.1 Conclusion 
The most looming hurdle of siRNA-based therapeutics has been the lack of a reliable 
carrier.  The overall goal of this dissertation is to develop more effective carriers for 
systemic delivery of siRNA to the tumors.  As a result, I have investigated 
biophysical properties that are critical for stable polyplex formation.   Furthermore, 
the HK peptide was modified with PEG and ligand cRGD to enhance the recognition 
and specificity at target tissues.  The physical characterizations and chemical 
modifications were utilized to investigate and optimize HK peptide carriers. 
 
Histidines of HK peptides were initially viewed as buffering agents that would aid the 
release of siRNA.  However, previous studies suggested that histidines might play a 
role in stabilization against serum-induced degradation.  In chapter 2, we analyzed 
thermodynamic binding of siRNA and peptides differing in sequences or number of 
branches.  The exothermicity of histidine-containing peptides suggested the presence 
of non-ionic interaction.  Using a 15N selectively labeled peptide, we determined that 
histidines mediate hydrogen bonding with siRNA and enhance the stability of 
polyplexes.  
 
To enhance the pharmacokinetics of polyplex, the most effective carrier H3K(+H)4b 




3, in vitro and biophysical characteristics of these modified HK/siRNA polyplexes 
(delayed migration on gel, size, surface charge, morphology and cell culture studies) 
have been determined and correlated with silencing tumor targets in a mouse model.  
It was observed that PEGylation inhibited binding of the peptide to siRNA.  To 
produce stable polyplexes with PEGylated H3K(+H)4b and siRNA, we showed that it 
is important to incorporate an unmodified H2K4b that has greater charge density in 
the two-step mixing procedure.  With an in vivo bioluminescence assay, we found 
that unmodified peptide was the most effective carrier in vitro, whereas the polyplex 
containing (RGD-PEG)4H3K(+H)4b down-regulated luciferase expression most 
effectively by 75% in vivo.  Moreover, we found that the enhanced gene silencing 
activity was correlated to the number of cRGD-PEG per peptide molecule and was 
not a result of cytokine induction.  Notably, the commonly used practice of utilizing 
only effective carriers in vitro for in vivo study may not result in identification of 
effective carriers.  
 
In chapter 4, we continued studying the pharmacokinetics and biodistribution of the 
most effective carrier, (RGD-PEG)4H3K(+H)4b (RP-HK), determined in chapter 3.  
Pharmacokinetic parameters such as serum half-life, area under curve, and tumor 
localization of RP-HK polyplex are enhanced by 3 to 5 times compared to 
unmodified polyplexes.  Importantly, the improved pharmacokinetics were correlated 
to greater gene silencing in tumor xenograft models.  Whereas tumor size was 
inhibited by 60%, Raf-1 target gene was inhibited by 90%, showing that RP-HK is a 




efficacy, it is important to target alternative oncogenes (e.g., survivin) or block 
additional pathways with the combination of chemotherapeutics (e.g., PI3K and 
Bcl2).  
 
In conclusion, this dissertation provides insights in characterization of biophysical 
properties that are critical to the biological activity of peptide/siRNA polyplexes.  We 
also synthesized chemically modified HK peptide in which siRNA could be delivered 
in vivo more effectively.   
 
5.2 Future work 
The ultimate goal of work like this is to establish an evidence-based approach to 
screen carrier candidates.  Experimental investigation of the binding mechanism and 
dynamic structural adjustments of siRNA polyplex self-assembly are expected to 
dictate silencing activity.  For example, we have found correlations between the 
entropy-driven process in the ITC profile and in vitro transfection efficiency (data not 
shown): the condensing process with an enthalpy greater than 20 kcal/mol may 
prevent the decomplexation and reduce release of siRNA.  Furthermore, this 
endothermic binding is likely to correlate with the content of lysines.  Therefore, 
lysines not only provide an electrostatic driving force to promote histidine-mediated 
hydrogen bonding, they also play an important role in electrostatic polyplex 
aggregation.  To determine optimal binding, peptides differing in the length of 




ITC to correlate their hydrogen bonding potentials and thermodynamic profiles with 
transfection results in vitro and in vivo.  This study is expected to open the door for 
reorientation of current procedures for the evaluation of transfection agents.   
 
One of the unanswered questions left in the chapter 2 is the nature of the assembled 
structure of HK/siRNA polyplexes and the change induced by electrostatic versus 
nonelectrostatic interactions.  The molecular origin of peptide/siRNA binding may 
provide more insight into the design of peptide sequence.  To gain the information of 
binding interface, we will collaborate with Dr. Jana Shen at School of Pharmacy to 
develop computer simulation tools.  Using a coarse-grained polymer model and the 
constant pH molecular dynamics technique (Wallace and Shen 2012; Fu, Markegard 
et al. 2013), accurate electrostatic calculations and large-scale molecular dynamic 
simulations for peptide/siRNA self-assembly process can be performed.  We will also 
synthesize singly labeled linear HK peptide, corresponding to a branch of the 
branched peptide, to obtain residue-specific characterizations with NMR.  The 
information obtained from ITC, NMR, and simulations will be systemically analyzed 
to identify the correlation between biophysical properties and biological activities.  
Moreover, through the collaboration with Dr. Seog and Dr. Kahn, the peptide/siRNA 
condensation and decomplexation process may be studied at a single molecule level, 
and the morphology and mechanical properties of polyplexes may be investigated 





In chapter 2, we discovered that although the unmodified peptide is a more effective 
carrier for siRNA delivery in vitro, the cRGD-PEG modified peptide shows 
significantly greater delivery efficiency in vivo.  Contradictory results between  in 
vitro and in vivo studies have also been observed by other groups (Whitehead, 
Matthews et al. 2012).  To improve in vitro/in vivo translatability, the effects of 
different routes of delivery to the trafficking of siRNA polyplexes will be elucidated.  
Anderson’s group has recently shown that the kinetics of assembly and disassembly 
of siRNA complexes can be tracked by FRET-labeled siRNA (Alabi, Love et al. 
2012).  Although this approach is currently limited to cell culture experiments, it will 
be interesting to study unpackaging of nucleic acids in vivo to correlate with 
complexation properties of polyplexes derived from biophysical experiments.  A 
fundamental understanding of polyplex disassembly in vivo may also reveal whether 
other factors such as polyplex-serum interaction or specific tumor type responses are 
involved. 
 
In the antitumor efficacy experiment, it appears that even though the Raf-1 oncogene 
was downregulated by 90%, tumor growth inhibition was not as significant as target 
gene silencing.  As discussed in the chapter 4, cross-talk and feedback compensation 
between oncogenic signal transduction pathways may play an important role in tumor 
cell proliferation.  To reduce the tumor growth more effectively, alternative genes and 
pathways should be targeted.  Preliminary data has shown that at least in vitro, siRNA 
targeted to survivin reduces viability of cancer cells more effectively than Raf-1 




surivin siRNA with Raf-1 in a xenograft model with cRGD-PEG modified HK 
peptides.   
 
In addition to replacing Raf-1 with survivin siRNA, the combination of chemotherapy 
and siRNA therapy will also be further examined to promote synergistic tumor 
suppression.  Docetaxel is an FDA approved anti-mitotic chemotherapeutic agent 
which has been used for treatment of breast, ovarian, prostate, and lung cancer 
(Clarke and Rivory 1999; Lyseng-Williamson and Fenton 2005; Michael, Syrigos et 
al. 2009).  The goal of combining docetaxel and siRNA is to inhibit the tumor growth 
more effectively and to lower the dosage of docetaxel to minimize the side effects.  
This delivery platform and strategy may increase the applicability of these therapies 
for clinical trials. 
 
To advance the HK/siRNA polyplex towards clinical trials, it is important to improve 
the stability of the polyplex.  As discussed in the chapter 4, increasing the level of 
PEGylation of polyplexes may significantly prolong the serum half-life.  However, it 
may be difficult for heavily PEGylated peptides to form polyplexes with siRNA.  
Moreover, heavily PEGylated polyplexes may also reduce the interaction with the cell 
membrane and thus, decrease cellular uptake.  Post-PEGylation of HK/siRNA 
polyplexes may be an alternative approaches to minimize influence of PEG to 
peptide/siRNA binding and polyplex formation.  In addition to shielding the polyplex 
with PEG, there are alternative approaches to enhance the stability.  For example, as I 




the polymeric micelles structure can be enhanced through disulfide cross-linking 
(Christie, Matsumoto et al. 2012).  As for HK peptides, cysteines added to the 
terminals of branched peptides can be oxidized to cross-link RP-HK peptides.  The 
preliminary data shows that the cross-linked RP-HK polyplex down-regulates 50% of 
the luciferase expression in the tumor xenografts compared with untreated groups.  It 
will be interesting to determine whether the cross-linked RP-HK polyplex maintains 
gene silencing ability with long-term enzymatic stress.   
 
Most of the efficacious polyplexes or lipoplexes are prepared by mixing and self-
assembly of carriers and siRNA.  A further challenge of RNAi therapteutics is the 
scale-up of the production of nanoplexes from small doses for mice to larger doses in 
humans.  Incomplete mixing may result in heterogeneity in the biophysical properties 
of nanoparticles which are likely to create variance in their biological activity.  The 
use of microfluidic devices for mixing may be a scalable technique to produce 
monodisperse polyplexes or lipoplexes (Belliveau, Huft et al. 2012; Chen, Love et al. 
2012).  Precisely controlled mixing process with microfluidic bioreactors has the 
advantage of preparing reproducibly homogenous nanomaterials that are sensitive to 
the concentration upon mixing.  It is anticipated that microfluidic devices will 
facilitate the production of HK/siRNA polyplexes at the clinical scale. 
 
To advance the HK/siRNA polyplex towards clinical trials, it is important to improve 
the stability of the polyplex.  As discussed in the chapter 4, increasing the level of 




may be difficult for heavily PEGylated peptides to form polyplexes with siRNA.  
Moreover, the uptake and the release of payloads may also be potential problems for 
heavily PEGylated polyplexes.  Post-PEGylation of HK/siRNA polyplexes may be an 
alternative approaches to minimize influence of PEG to peptide/siRNA binding and 
polyplex formation.  In addition to shielding the polyplex with PEG, there are 
alternative approaches to enhance the stability.  For example, as discussed in the 
Introduction, Kataoka’s group has shown that the stability of the polymeric micelles 
structure can be enhanced through disulfide cross-linking (Christie, Matsumoto et al. 
2012).  As for HK peptides, cysteines added to the terminals of branched peptides can 
be oxidized to cross-link RP-HK peptides.  The preliminary data shows that the cross-
linked RP-HK polyplex down-regulates 50% of the luciferase expression in the tumor 
xenografts compared with untreated groups.  It will be interesting to determine 
whether the cross-linked RP-HK polyplex maintains gene silencing ability with long-
term enzymatic stress.   
 
Most of the efficacious polyplexes or lipoplexes are prepared by mixing and self-
assembly of carriers and siRNA.  A further challenge of RNAi therapteutics is the 
scale-up of the production of nanoplexes from small doses for mice to larger doses in 
humans.  Incomplete mixing may result in heterogeneity in the biophysical properties 
of nanoparticles which are likely to create variance in their biological activity.  The 
use of microfluidic devices for mixing may be a scalable technique to produce 
monodisperse polyplexes or lipoplexes (Belliveau, Huft et al. 2012; Chen, Love et al. 




advantage of preparing reproducibly homogenous nanomaterials that are sensitive to 
the concentration upon mixing.  It is anticipated that microfluidic devices will 
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